[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f2q-MMtG86rnyIVA8xm6jUEzErXu0RrjY9OcwT_aqg9k":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":81,"rows":88},"BioNTech SE",[4],71,false,30,20,123783,69,1,[14,16,19,22,25,27,29,32],{"name":15,"count":9},"COVID-19",{"name":17,"count":18},"SARS-CoV-2 Infection",12,{"name":20,"count":21},"Solid Tumor",5,{"name":23,"count":24},"Non-small Cell Lung Cancer",3,{"name":26,"count":24},"Advanced Solid Tumor",{"name":28,"count":24},"SARS-COV-2 Infection",{"name":30,"count":31},"Extensive-stage Small-cell Lung Cancer",2,{"name":33,"count":31},"Influenza",[35,40,45,50,54,59,64,69,73,77],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05547464","Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","2026-03-12","BNT164a1",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05543616","A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children","2026-07-23","Bivalent BNT162b2 (original\u002FOmicron BA.4\u002FBA.5) 3 microgram dose",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT07222384","A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19","2026-07-31","BNT162b2",{"nctId":51,"briefTitle":52,"date":48,"intervention":53},"NCT07300839","A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age","BNT162b2 Vaccine",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05432583","A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions","2026-10","BNT163",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04486378","A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer","2026-11","RO7198457 intravenous",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06449209","Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","2027-06","BNT327 Dose Level 1",{"nctId":70,"briefTitle":71,"date":67,"intervention":72},"NCT06150183","Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors","BNT314",{"nctId":74,"briefTitle":75,"date":67,"intervention":76},"NCT07379580","A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa","BNT166a",{"nctId":78,"briefTitle":79,"date":67,"intervention":80},"NCT07392372","A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV","BNT351",[82,83,84,85,86,87],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[89,206,291,334,373,416,459,485,507,536,711,733,771,793,815,833,851,869,887,905,923,941,959,977,995,1015,1062,1084,1106,1128,1153,1175,1204,1238,1271,1293,1311,1329,1347,1365,1383,1401,1419,1445,1463,1488,1506,1524,1547,1565,1583,1601,1619,1661,1682,1700,1718,1736,1754,1772,1790,1808,1838,1856,1874,1892,1910,1928,1946,1967,2023,2055,2077,2095,2113,2131,2149,2167,2185,2213,2231,2249,2267,2285,2303,2321,2339,2367,2385,2403,2421,2443,2465,2491,2517,2535,2553,2571,2589,2607,2625,2643,2661,2685,2703,2721,2739,2757,2775,2799,2817,2846,2864,2882,2900,2918,2944,2962,2980,2998,3016,3041,3059,3077,3102,3131,3149,3167,3185,3203,3221,3245,3270,3297],{"intervention":90,"totalTrials":91,"cells":92},"Pumitamig",8,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":161,"PHASE4":202,"NA":204},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":21,"soonestReadout":155},[100,111,124,138,151],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT06841055","Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","RECRUITING",[84],"2028-10","2025-03-03",60,[23],[90,110],"Docetaxel",{"nctId":112,"briefTitle":113,"status":103,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":121},"NCT07297212","A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma",[84],"2028-01","2029-07","2026-01-15",75,[120],"Recurrent Glioblastoma",[90,122,123],"Bevacizumab","Temozolomide",{"nctId":125,"briefTitle":126,"status":103,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"NCT07255404","A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer",[84],"2027-12","2028-08","2025-12-04",105,[133],"Pancreatic Ductal Adenocarcinoma (PDAC)",[90,135,136,137],"Nab-paclitaxel","Gemcitabine","mFOLFIRINOX",{"nctId":139,"briefTitle":140,"status":103,"phases":141,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"NCT07070232","A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors",[83,84],"2028-02","2029-10","2025-08-12",980,[26],[148,90,149,150],"BNT326","Itraconazole","Paroxetine",{"nctId":152,"briefTitle":153,"status":103,"phases":154,"primaryCompletion":155,"completion":129,"start":156,"enrollment":157,"conditions":158,"interventions":159},"NCT07147348","A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors",[83,84],"2027-11","2025-08-27",375,[26],[160,90],"BNT3212",{"trials":162,"activeCount":24,"soonestReadout":167},[163,176,189],{"nctId":164,"briefTitle":165,"status":103,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT06712355","Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer",[85],"2028-12","2029-03","2025-02-03",621,[30],[90,173,174,175],"Atezolizumab","Etoposide","Carboplatin",{"nctId":177,"briefTitle":178,"status":103,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":185},"NCT06712316","Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer",[84,85],"2029-02","2030-03","2025-01-07",1260,[23],[90,186,175,187,188],"Pembrolizumab","Pemetrexed","Paclitaxel",{"nctId":190,"briefTitle":191,"status":103,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":199},"NCT07173751","ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer",[85],"2029-12","2030-09","2025-10-30",558,[198],"Breast Neoplasms",[90,200,136,175,201],"Nab-paclitaxel\u002FPaclitaxel","Eribulin",{"trials":203,"activeCount":95},[],{"trials":205,"activeCount":95},[],{"intervention":175,"totalTrials":207,"cells":208},7,{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":232,"PHASE3":273,"PHASE4":287,"NA":289},{"trials":210,"activeCount":95},[],{"trials":212,"activeCount":12,"soonestReadout":217},[213],{"nctId":214,"briefTitle":215,"status":103,"phases":216,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"NCT05142189","Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer",[83],"2030-02","2031-11","2022-06-17",320,[222],"Non-Small Cell Lung Cancer",[224,225,110,175,188,226,227,228,229,230,231],"BNT116","Cemiplimab","BNT316","anti-B7-H3 antibody conjugated to topoisomerase I inhibitor","anti-HER3 antibody conjugated to topoisomerase I inhibitor","Bispecific antibody for PD-L1 and VEGF-A","Osimertinib","ALK-inhibitor or RET-inhibitor",{"trials":233,"activeCount":31,"soonestReadout":67},[234,245,260],{"nctId":65,"briefTitle":66,"status":235,"phases":236,"primaryCompletion":67,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":242},"ACTIVE_NOT_RECRUITING",[84],"2028-05","2024-08-05",110,[30,241],"Small-cell Lung Cancer",[68,243,174,175,188,244],"BNT327 Dose Level 2","Topotecan",{"nctId":246,"briefTitle":247,"status":235,"phases":248,"primaryCompletion":129,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":256},"NCT06449222","Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy",[84],"2029-06","2024-08-26",83,[253,254,255],"Locally Advanced Breast Cancer","Triple Negative Breast Cancer","Metastatic Triple Negative Breast Cancers",[68,68,257,175,136,188,201,258,259],"Nab-placlitaxel","BNT327 Optimized Dose","BNT327 Equivalent Q3W Dose",{"nctId":261,"briefTitle":262,"status":263,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":271},"NCT04101357","Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411","TERMINATED",[83,84],"2024-01-19","2024-05-23","2020-06-19",54,[20,270],"Extensive-stage Small Cell Lung Cancer",[272,173,175,174],"BNT411",{"trials":274,"activeCount":24,"soonestReadout":167},[275,279,283],{"nctId":164,"briefTitle":165,"status":103,"phases":276,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":277,"interventions":278},[85],[30],[90,173,174,175],{"nctId":177,"briefTitle":178,"status":103,"phases":280,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":281,"interventions":282},[84,85],[23],[90,186,175,187,188],{"nctId":190,"briefTitle":191,"status":103,"phases":284,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":285,"interventions":286},[85],[198],[90,200,136,175,201],{"trials":288,"activeCount":95},[],{"trials":290,"activeCount":95},[],{"intervention":188,"totalTrials":21,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":301,"PHASE3":311,"PHASE4":330,"NA":332},{"trials":294,"activeCount":95},[],{"trials":296,"activeCount":12,"soonestReadout":217},[297],{"nctId":214,"briefTitle":215,"status":103,"phases":298,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":299,"interventions":300},[83],[222],[224,225,110,175,188,226,227,228,229,230,231],{"trials":302,"activeCount":31,"soonestReadout":67},[303,307],{"nctId":65,"briefTitle":66,"status":235,"phases":304,"primaryCompletion":67,"completion":237,"start":238,"enrollment":239,"conditions":305,"interventions":306},[84],[30,241],[68,243,174,175,188,244],{"nctId":246,"briefTitle":247,"status":235,"phases":308,"primaryCompletion":129,"completion":249,"start":250,"enrollment":251,"conditions":309,"interventions":310},[84],[253,254,255],[68,68,257,175,136,188,201,258,259],{"trials":312,"activeCount":31,"soonestReadout":317},[313,326],{"nctId":314,"briefTitle":315,"status":103,"phases":316,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":323},"NCT06340568","A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer",[85],"2028-03","2029-11","2025-06-10",480,[322],"Endometrial Cancer",[324,325,188,110],"BNT323\u002FDB-1303","Doxorubicin",{"nctId":177,"briefTitle":178,"status":103,"phases":327,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":328,"interventions":329},[84,85],[23],[90,186,175,187,188],{"trials":331,"activeCount":95},[],{"trials":333,"activeCount":95},[],{"intervention":110,"totalTrials":335,"cells":336},4,{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":345,"PHASE3":351,"PHASE4":369,"NA":371},{"trials":338,"activeCount":95},[],{"trials":340,"activeCount":12,"soonestReadout":217},[341],{"nctId":214,"briefTitle":215,"status":103,"phases":342,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":343,"interventions":344},[83],[222],[224,225,110,175,188,226,227,228,229,230,231],{"trials":346,"activeCount":12,"soonestReadout":105},[347],{"nctId":101,"briefTitle":102,"status":103,"phases":348,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":349,"interventions":350},[84],[23],[90,110],{"trials":352,"activeCount":31,"soonestReadout":317},[353,357],{"nctId":314,"briefTitle":315,"status":103,"phases":354,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":355,"interventions":356},[85],[322],[324,325,188,110],{"nctId":358,"briefTitle":359,"status":103,"phases":360,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":366},"NCT07365995","A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer",[85],"2031-02","2026-04-22",736,[365],"Metastatic Castration-resistant Prostate Cancer",[367,110,368],"BNT324","Prednisone\u002Fprednisolone",{"trials":370,"activeCount":95},[],{"trials":372,"activeCount":95},[],{"intervention":136,"totalTrials":335,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":406,"PHASE4":412,"NA":414},{"trials":376,"activeCount":95},[],{"trials":378,"activeCount":95},[],{"trials":380,"activeCount":31,"soonestReadout":128},[381,385,402],{"nctId":246,"briefTitle":247,"status":235,"phases":382,"primaryCompletion":129,"completion":249,"start":250,"enrollment":251,"conditions":383,"interventions":384},[84],[253,254,255],[68,68,257,175,136,188,201,258,259],{"nctId":386,"briefTitle":387,"status":263,"phases":388,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":400},"NCT04683939","Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors",[83,84],"2023-07-24","2022-01-18",13,[20,393,394,395,396,397,398,399],"Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma","Pancreatic Cancer","Biliary Tract Cancer","Cholangiocarcinoma","Metastatic Cancer",[401,135,136],"BNT141",{"nctId":125,"briefTitle":126,"status":103,"phases":403,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":404,"interventions":405},[84],[133],[90,135,136,137],{"trials":407,"activeCount":12,"soonestReadout":193},[408],{"nctId":190,"briefTitle":191,"status":103,"phases":409,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":410,"interventions":411},[85],[198],[90,200,136,175,201],{"trials":413,"activeCount":95},[],{"trials":415,"activeCount":95},[],{"intervention":186,"totalTrials":24,"cells":417},{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":436,"PHASE4":455,"NA":457},{"trials":419,"activeCount":95},[],{"trials":421,"activeCount":95},[],{"trials":423,"activeCount":12,"soonestReadout":428},[424],{"nctId":425,"briefTitle":426,"status":103,"phases":427,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":433},"NCT07111520","A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)",[83,84],"2029-01","2030-01","2025-09-22",420,[23],[148,434,186,435],"BNT327","SoC",{"trials":437,"activeCount":31,"soonestReadout":180},[438,442],{"nctId":177,"briefTitle":178,"status":103,"phases":439,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":440,"interventions":441},[84,85],[23],[90,186,175,187,188],{"nctId":443,"briefTitle":444,"status":103,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":453},"NCT04534205","A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1",[84,85],"2029-04","2021-01-07",350,[450,451,452],"Unresectable Head and Neck Squamous Cell Carcinoma","Metastatic Head and Neck Cancer","Recurrent Head and Neck Cancer",[454,186],"BNT113",{"trials":456,"activeCount":95},[],{"trials":458,"activeCount":95},[],{"intervention":174,"totalTrials":24,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":475,"PHASE4":481,"NA":483},{"trials":462,"activeCount":95},[],{"trials":464,"activeCount":95},[],{"trials":466,"activeCount":12,"soonestReadout":67},[467,471],{"nctId":65,"briefTitle":66,"status":235,"phases":468,"primaryCompletion":67,"completion":237,"start":238,"enrollment":239,"conditions":469,"interventions":470},[84],[30,241],[68,243,174,175,188,244],{"nctId":261,"briefTitle":262,"status":263,"phases":472,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":473,"interventions":474},[83,84],[20,270],[272,173,175,174],{"trials":476,"activeCount":12,"soonestReadout":167},[477],{"nctId":164,"briefTitle":165,"status":103,"phases":478,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":479,"interventions":480},[85],[30],[90,173,174,175],{"trials":482,"activeCount":95},[],{"trials":484,"activeCount":95},[],{"intervention":201,"totalTrials":31,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":497,"PHASE4":503,"NA":505},{"trials":488,"activeCount":95},[],{"trials":490,"activeCount":95},[],{"trials":492,"activeCount":12,"soonestReadout":129},[493],{"nctId":246,"briefTitle":247,"status":235,"phases":494,"primaryCompletion":129,"completion":249,"start":250,"enrollment":251,"conditions":495,"interventions":496},[84],[253,254,255],[68,68,257,175,136,188,201,258,259],{"trials":498,"activeCount":12,"soonestReadout":193},[499],{"nctId":190,"briefTitle":191,"status":103,"phases":500,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":501,"interventions":502},[85],[198],[90,200,136,175,201],{"trials":504,"activeCount":95},[],{"trials":506,"activeCount":95},[],{"intervention":367,"totalTrials":31,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":526,"PHASE4":532,"NA":534},{"trials":510,"activeCount":95},[],{"trials":512,"activeCount":95},[],{"trials":514,"activeCount":12,"soonestReadout":519},[515],{"nctId":516,"briefTitle":517,"status":103,"phases":518,"primaryCompletion":519,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":525},"NCT06892548","A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer",[83,84],"2027-08","2031-06","2025-05-02",594,[524],"Advanced Lung Cancer",[367,434],{"trials":527,"activeCount":12,"soonestReadout":361},[528],{"nctId":358,"briefTitle":359,"status":103,"phases":529,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":530,"interventions":531},[85],[365],[367,110,368],{"trials":533,"activeCount":95},[],{"trials":535,"activeCount":95},[],{"intervention":49,"totalTrials":537,"cells":538},15,{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":611,"PHASE4":698,"NA":709},{"trials":540,"activeCount":95},[],{"trials":542,"activeCount":95},[],{"trials":544,"activeCount":95},[545,560,570,581,600],{"nctId":546,"briefTitle":547,"status":548,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":557},"NCT05004181","Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants","COMPLETED",[84],"2023-08-16","2023-10-04","2021-08-25",1380,[17,15,555,556],"SARS-CoV-2 Acute Respiratory Disease","SARS (Disease)",[49,558,559,559,559],"Multivalent BNT162b2","Monovalent BNT162b2",{"nctId":561,"briefTitle":562,"status":548,"phases":563,"primaryCompletion":564,"completion":564,"start":565,"enrollment":566,"conditions":567,"interventions":569},"NCT04895982","Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years",[84],"2023-07-23","2021-10-15",124,[568],"SARS-CoV-2 Infection, COVID19",[49],{"nctId":571,"briefTitle":572,"status":548,"phases":573,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":579},"NCT04949490","A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects",[84],"2022-04-14","2022-09-16","2021-07-26",137,[15,17],[580,49],"BNT162b2s01",{"nctId":582,"briefTitle":583,"status":548,"phases":584,"primaryCompletion":585,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":596},"NCT04380701","A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults",[83,84],"2021-06-30","2022-04-13","2020-04-23",512,[590,591,592,593,594,595],"Infections, Respiratory","Virus Diseases","Infection Viral","Vaccine Adverse Reaction","RNA Virus Infections","Protection Against COVID-19 and Infections With SARS CoV 2",[597,598,49,599],"BNT162a1","BNT162b1","BNT162c2",{"nctId":601,"briefTitle":602,"status":548,"phases":603,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":610},"NCT04649021","Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population",[84],"2021-02-07","2022-01-09","2020-12-04",960,[609],"SARS-CoV-2",[49],{"trials":612,"activeCount":12,"soonestReadout":48},[613,623,633,643,653,662,672,677,686],{"nctId":614,"briefTitle":615,"status":548,"phases":616,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":622},"NCT04754594","To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older",[84,85],"2022-07-15","2021-02-16",726,[17,15,621],"Maternal Immunization",[49],{"nctId":624,"briefTitle":625,"status":548,"phases":626,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":632},"NCT04816669","A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults",[85],"2021-12-01","2021-12-02","2021-04-01",629,[17,15],[49],{"nctId":634,"briefTitle":635,"status":548,"phases":636,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":641},"NCT05310084","Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age",[85],"2022-10-05","2022-04-20",1134,[17,15],[49,642],"Seasonal Inactivated Influenza Vaccine",{"nctId":644,"briefTitle":645,"status":548,"phases":646,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":651},"NCT04368728","Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",[84,85],"2023-02-10","2020-04-29",46969,[17,15],[598,49,652],"BNT162b2SA",{"nctId":654,"briefTitle":655,"status":548,"phases":656,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":661},"NCT05997290","A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals",[84,85],"2025-03-13","2023-08-10",1051,[17,15],[49,49,49],{"nctId":663,"briefTitle":664,"status":548,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":670},"NCT04713553","A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants",[85],"2021-07-22","2021-02-15",1574,[17,15],[49,671],"BNT162b2.B.1.351",{"nctId":46,"briefTitle":47,"status":235,"phases":673,"primaryCompletion":48,"completion":48,"start":195,"enrollment":674,"conditions":675,"interventions":676},[85],343,[15,28],[49],{"nctId":678,"briefTitle":679,"status":548,"phases":680,"primaryCompletion":681,"completion":681,"start":682,"enrollment":683,"conditions":684,"interventions":685},"NCT07069309","A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years",[85],"2026-05-01","2025-07-08",774,[15,28],[49],{"nctId":687,"briefTitle":688,"status":548,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":694},"NCT04955626","To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.",[85],"2023-05-25","2021-07-01",16372,[17,15],[49,695,696,697],"BNT162b2 OMI","Combination BNT162b2 and BNT162b2 OMI","Combination (Bivalent) BNT162b2 and BNT162b2 OMI",{"trials":699,"activeCount":95},[700],{"nctId":701,"briefTitle":702,"status":548,"phases":703,"primaryCompletion":704,"completion":704,"start":705,"enrollment":706,"conditions":707,"interventions":708},"NCT04588480","Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults",[86],"2021-11-25","2020-10-21",160,[17,15],[49],{"trials":710,"activeCount":95},[],{"intervention":173,"totalTrials":31,"cells":712},{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":723,"PHASE4":729,"NA":731},{"trials":714,"activeCount":95},[],{"trials":716,"activeCount":95},[],{"trials":718,"activeCount":95},[719],{"nctId":261,"briefTitle":262,"status":263,"phases":720,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":721,"interventions":722},[83,84],[20,270],[272,173,175,174],{"trials":724,"activeCount":12,"soonestReadout":167},[725],{"nctId":164,"briefTitle":165,"status":103,"phases":726,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":727,"interventions":728},[85],[30],[90,173,174,175],{"trials":730,"activeCount":95},[],{"trials":732,"activeCount":95},[],{"intervention":44,"totalTrials":31,"cells":734},{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":751,"PHASE3":753,"PHASE4":767,"NA":769},{"trials":736,"activeCount":95},[],{"trials":738,"activeCount":95},[739],{"nctId":740,"briefTitle":741,"status":742,"phases":743,"primaryCompletion":744,"completion":744,"start":745,"enrollment":95,"conditions":746,"interventions":747},"NCT05630352","A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children","WITHDRAWN",[83],"2026-07-13","2025-01-06",[15],[44,748,749,750],"Bivalent BNT162b2 (original\u002FOmicron BA.4\u002FBA.5) 6 microgram dose","Bivalent BNT162b2 (original\u002FOmicron BA.4\u002FBA.5) 10 microgram dose","Bivalent BNT162b2 (original\u002FOmicron BA.4\u002FBA.5) 1 microgram dose",{"trials":752,"activeCount":95},[],{"trials":754,"activeCount":12,"soonestReadout":43},[755],{"nctId":41,"briefTitle":42,"status":235,"phases":756,"primaryCompletion":43,"completion":43,"start":757,"enrollment":758,"conditions":759,"interventions":762},[85],"2022-09-23",4292,[760,761,15],"SARS-CoV-2 Virus","Severe Acute Respiratory Syndrome Coronavirus 2",[44,748,749,763,764,765,766],"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose","Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose","Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose",{"trials":768,"activeCount":95},[],{"trials":770,"activeCount":95},[],{"intervention":748,"totalTrials":31,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":781,"PHASE3":783,"PHASE4":789,"NA":791},{"trials":774,"activeCount":95},[],{"trials":776,"activeCount":95},[777],{"nctId":740,"briefTitle":741,"status":742,"phases":778,"primaryCompletion":744,"completion":744,"start":745,"enrollment":95,"conditions":779,"interventions":780},[83],[15],[44,748,749,750],{"trials":782,"activeCount":95},[],{"trials":784,"activeCount":12,"soonestReadout":43},[785],{"nctId":41,"briefTitle":42,"status":235,"phases":786,"primaryCompletion":43,"completion":43,"start":757,"enrollment":758,"conditions":787,"interventions":788},[85],[760,761,15],[44,748,749,763,764,765,766],{"trials":790,"activeCount":95},[],{"trials":792,"activeCount":95},[],{"intervention":749,"totalTrials":31,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":803,"PHASE3":805,"PHASE4":811,"NA":813},{"trials":796,"activeCount":95},[],{"trials":798,"activeCount":95},[799],{"nctId":740,"briefTitle":741,"status":742,"phases":800,"primaryCompletion":744,"completion":744,"start":745,"enrollment":95,"conditions":801,"interventions":802},[83],[15],[44,748,749,750],{"trials":804,"activeCount":95},[],{"trials":806,"activeCount":12,"soonestReadout":43},[807],{"nctId":41,"briefTitle":42,"status":235,"phases":808,"primaryCompletion":43,"completion":43,"start":757,"enrollment":758,"conditions":809,"interventions":810},[85],[760,761,15],[44,748,749,763,764,765,766],{"trials":812,"activeCount":95},[],{"trials":814,"activeCount":95},[],{"intervention":324,"totalTrials":12,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":829,"NA":831},{"trials":818,"activeCount":95},[],{"trials":820,"activeCount":95},[],{"trials":822,"activeCount":95},[],{"trials":824,"activeCount":12,"soonestReadout":317},[825],{"nctId":314,"briefTitle":315,"status":103,"phases":826,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":827,"interventions":828},[85],[322],[324,325,188,110],{"trials":830,"activeCount":95},[],{"trials":832,"activeCount":95},[],{"intervention":325,"totalTrials":12,"cells":834},{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":847,"NA":849},{"trials":836,"activeCount":95},[],{"trials":838,"activeCount":95},[],{"trials":840,"activeCount":95},[],{"trials":842,"activeCount":12,"soonestReadout":317},[843],{"nctId":314,"briefTitle":315,"status":103,"phases":844,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":845,"interventions":846},[85],[322],[324,325,188,110],{"trials":848,"activeCount":95},[],{"trials":850,"activeCount":95},[],{"intervention":187,"totalTrials":12,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":865,"NA":867},{"trials":854,"activeCount":95},[],{"trials":856,"activeCount":95},[],{"trials":858,"activeCount":95},[],{"trials":860,"activeCount":12,"soonestReadout":180},[861],{"nctId":177,"briefTitle":178,"status":103,"phases":862,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":863,"interventions":864},[84,85],[23],[90,186,175,187,188],{"trials":866,"activeCount":95},[],{"trials":868,"activeCount":95},[],{"intervention":200,"totalTrials":12,"cells":870},{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":883,"NA":885},{"trials":872,"activeCount":95},[],{"trials":874,"activeCount":95},[],{"trials":876,"activeCount":95},[],{"trials":878,"activeCount":12,"soonestReadout":193},[879],{"nctId":190,"briefTitle":191,"status":103,"phases":880,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":881,"interventions":882},[85],[198],[90,200,136,175,201],{"trials":884,"activeCount":95},[],{"trials":886,"activeCount":95},[],{"intervention":454,"totalTrials":12,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":901,"NA":903},{"trials":890,"activeCount":95},[],{"trials":892,"activeCount":95},[],{"trials":894,"activeCount":95},[],{"trials":896,"activeCount":12,"soonestReadout":446},[897],{"nctId":443,"briefTitle":444,"status":103,"phases":898,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":899,"interventions":900},[84,85],[450,451,452],[454,186],{"trials":902,"activeCount":95},[],{"trials":904,"activeCount":95},[],{"intervention":368,"totalTrials":12,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":919,"NA":921},{"trials":908,"activeCount":95},[],{"trials":910,"activeCount":95},[],{"trials":912,"activeCount":95},[],{"trials":914,"activeCount":12,"soonestReadout":361},[915],{"nctId":358,"briefTitle":359,"status":103,"phases":916,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":917,"interventions":918},[85],[365],[367,110,368],{"trials":920,"activeCount":95},[],{"trials":922,"activeCount":95},[],{"intervention":763,"totalTrials":12,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":937,"NA":939},{"trials":926,"activeCount":95},[],{"trials":928,"activeCount":95},[],{"trials":930,"activeCount":95},[],{"trials":932,"activeCount":12,"soonestReadout":43},[933],{"nctId":41,"briefTitle":42,"status":235,"phases":934,"primaryCompletion":43,"completion":43,"start":757,"enrollment":758,"conditions":935,"interventions":936},[85],[760,761,15],[44,748,749,763,764,765,766],{"trials":938,"activeCount":95},[],{"trials":940,"activeCount":95},[],{"intervention":764,"totalTrials":12,"cells":942},{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":949,"PHASE4":955,"NA":957},{"trials":944,"activeCount":95},[],{"trials":946,"activeCount":95},[],{"trials":948,"activeCount":95},[],{"trials":950,"activeCount":12,"soonestReadout":43},[951],{"nctId":41,"briefTitle":42,"status":235,"phases":952,"primaryCompletion":43,"completion":43,"start":757,"enrollment":758,"conditions":953,"interventions":954},[85],[760,761,15],[44,748,749,763,764,765,766],{"trials":956,"activeCount":95},[],{"trials":958,"activeCount":95},[],{"intervention":765,"totalTrials":12,"cells":960},{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":973,"NA":975},{"trials":962,"activeCount":95},[],{"trials":964,"activeCount":95},[],{"trials":966,"activeCount":95},[],{"trials":968,"activeCount":12,"soonestReadout":43},[969],{"nctId":41,"briefTitle":42,"status":235,"phases":970,"primaryCompletion":43,"completion":43,"start":757,"enrollment":758,"conditions":971,"interventions":972},[85],[760,761,15],[44,748,749,763,764,765,766],{"trials":974,"activeCount":95},[],{"trials":976,"activeCount":95},[],{"intervention":766,"totalTrials":12,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":985,"PHASE4":991,"NA":993},{"trials":980,"activeCount":95},[],{"trials":982,"activeCount":95},[],{"trials":984,"activeCount":95},[],{"trials":986,"activeCount":12,"soonestReadout":43},[987],{"nctId":41,"briefTitle":42,"status":235,"phases":988,"primaryCompletion":43,"completion":43,"start":757,"enrollment":758,"conditions":989,"interventions":990},[85],[760,761,15],[44,748,749,763,764,765,766],{"trials":992,"activeCount":95},[],{"trials":994,"activeCount":95},[],{"intervention":53,"totalTrials":12,"cells":996},{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1003,"PHASE4":1011,"NA":1013},{"trials":998,"activeCount":95},[],{"trials":1000,"activeCount":95},[],{"trials":1002,"activeCount":95},[],{"trials":1004,"activeCount":12,"soonestReadout":48},[1005],{"nctId":51,"briefTitle":52,"status":235,"phases":1006,"primaryCompletion":48,"completion":48,"start":1007,"enrollment":1008,"conditions":1009,"interventions":1010},[85],"2025-12-10",5240,[15,28],[53],{"trials":1012,"activeCount":95},[],{"trials":1014,"activeCount":95},[],{"intervention":434,"totalTrials":335,"cells":1016},{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1018,"activeCount":95},[],{"trials":1020,"activeCount":95},[],{"trials":1022,"activeCount":335,"soonestReadout":519},[1023,1027,1039,1043],{"nctId":425,"briefTitle":426,"status":103,"phases":1024,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":1025,"interventions":1026},[83,84],[23],[148,434,186,435],{"nctId":1028,"briefTitle":1029,"status":103,"phases":1030,"primaryCompletion":237,"completion":1031,"start":1032,"enrollment":1033,"conditions":1034,"interventions":1037},"NCT06827236","A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer",[83,84],"2029-05","2025-04-23",380,[253,1035,1036],"Unresectable Breast Carcinoma","Metastatic Breast Cancer",[1038,434],"BNT323",{"nctId":516,"briefTitle":517,"status":103,"phases":1040,"primaryCompletion":519,"completion":520,"start":521,"enrollment":522,"conditions":1041,"interventions":1042},[83,84],[524],[367,434],{"nctId":1044,"briefTitle":1045,"status":103,"phases":1046,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":1050,"conditions":1051,"interventions":1053},"NCT07079631","A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer",[83,84],"2030-12","2031-05","2025-07-18",482,[1052],"Metastatic Colorectal Cancer",[72,434,1054,1055,122],"SoC chemotherapy treatment 1","SoC chemotherapy treatment 2",{"trials":1057,"activeCount":95},[],{"trials":1059,"activeCount":95},[],{"trials":1061,"activeCount":95},[],{"intervention":68,"totalTrials":31,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1065,"activeCount":95},[],{"trials":1067,"activeCount":95},[],{"trials":1069,"activeCount":31,"soonestReadout":67},[1070,1074],{"nctId":65,"briefTitle":66,"status":235,"phases":1071,"primaryCompletion":67,"completion":237,"start":238,"enrollment":239,"conditions":1072,"interventions":1073},[84],[30,241],[68,243,174,175,188,244],{"nctId":246,"briefTitle":247,"status":235,"phases":1075,"primaryCompletion":129,"completion":249,"start":250,"enrollment":251,"conditions":1076,"interventions":1077},[84],[253,254,255],[68,68,257,175,136,188,201,258,259],{"trials":1079,"activeCount":95},[],{"trials":1081,"activeCount":95},[],{"trials":1083,"activeCount":95},[],{"intervention":148,"totalTrials":31,"cells":1085},{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1100,"PHASE4":1102,"NA":1104},{"trials":1087,"activeCount":95},[],{"trials":1089,"activeCount":95},[],{"trials":1091,"activeCount":31,"soonestReadout":142},[1092,1096],{"nctId":425,"briefTitle":426,"status":103,"phases":1093,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":1094,"interventions":1095},[83,84],[23],[148,434,186,435],{"nctId":139,"briefTitle":140,"status":103,"phases":1097,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":1098,"interventions":1099},[83,84],[26],[148,90,149,150],{"trials":1101,"activeCount":95},[],{"trials":1103,"activeCount":95},[],{"trials":1105,"activeCount":95},[],{"intervention":122,"totalTrials":31,"cells":1107},{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1109,"activeCount":95},[],{"trials":1111,"activeCount":95},[],{"trials":1113,"activeCount":31,"soonestReadout":115},[1114,1118],{"nctId":112,"briefTitle":113,"status":103,"phases":1115,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":1116,"interventions":1117},[84],[120],[90,122,123],{"nctId":1044,"briefTitle":1045,"status":103,"phases":1119,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":1050,"conditions":1120,"interventions":1121},[83,84],[1052],[72,434,1054,1055,122],{"trials":1123,"activeCount":95},[],{"trials":1125,"activeCount":95},[],{"trials":1127,"activeCount":95},[],{"intervention":72,"totalTrials":31,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1141,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1131,"activeCount":95},[],{"trials":1133,"activeCount":12,"soonestReadout":67},[1134],{"nctId":70,"briefTitle":71,"status":235,"phases":1135,"primaryCompletion":67,"completion":317,"start":1136,"enrollment":1137,"conditions":1138,"interventions":1140},[83],"2023-11-30",41,[1139],"Advanced Malignant Solid Tumor",[72],{"trials":1142,"activeCount":12,"soonestReadout":1047},[1143],{"nctId":1044,"briefTitle":1045,"status":103,"phases":1144,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":1050,"conditions":1145,"interventions":1146},[83,84],[1052],[72,434,1054,1055,122],{"trials":1148,"activeCount":95},[],{"trials":1150,"activeCount":95},[],{"trials":1152,"activeCount":95},[],{"intervention":135,"totalTrials":31,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1156,"activeCount":95},[],{"trials":1158,"activeCount":95},[],{"trials":1160,"activeCount":12,"soonestReadout":128},[1161,1165],{"nctId":386,"briefTitle":387,"status":263,"phases":1162,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":1163,"interventions":1164},[83,84],[20,393,394,395,396,397,398,399],[401,135,136],{"nctId":125,"briefTitle":126,"status":103,"phases":1166,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":1167,"interventions":1168},[84],[133],[90,135,136,137],{"trials":1170,"activeCount":95},[],{"trials":1172,"activeCount":95},[],{"trials":1174,"activeCount":95},[],{"intervention":137,"totalTrials":31,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1178,"activeCount":95},[],{"trials":1180,"activeCount":95},[],{"trials":1182,"activeCount":12,"soonestReadout":128},[1183,1187],{"nctId":125,"briefTitle":126,"status":103,"phases":1184,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":1185,"interventions":1186},[84],[133],[90,135,136,137],{"nctId":1188,"briefTitle":1189,"status":263,"phases":1190,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":12,"conditions":1193,"interventions":1194},"NCT06069778","Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma",[83,84],"2024-09-18","2024-03-27",[396],[1195,1196,137,1197],"BNT321 0.5 mg\u002Fkg","BNT321 DL 2","BNT321 RP2D",{"trials":1199,"activeCount":95},[],{"trials":1201,"activeCount":95},[],{"trials":1203,"activeCount":95},[],{"intervention":76,"totalTrials":31,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1232,"PHASE4":1234,"NA":1236},{"trials":1207,"activeCount":95},[],{"trials":1209,"activeCount":95},[],{"trials":1211,"activeCount":12,"soonestReadout":67},[1212,1223],{"nctId":1213,"briefTitle":1214,"status":548,"phases":1215,"primaryCompletion":1216,"completion":1217,"start":1218,"enrollment":1219,"conditions":1220,"interventions":1222},"NCT05988203","A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines",[83,84],"2025-08-25","2026-03-04","2023-09-21",96,[1221],"Monkeypox",[76],{"nctId":74,"briefTitle":75,"status":103,"phases":1224,"primaryCompletion":67,"completion":67,"start":1225,"enrollment":1226,"conditions":1227,"interventions":1231},[84],"2026-02-20",310,[1228,1229,1230],"Mpox (Monkeypox)","Smallpox","Orthopoxvirus Infection",[76],{"trials":1233,"activeCount":95},[],{"trials":1235,"activeCount":95},[],{"trials":1237,"activeCount":95},[],{"intervention":39,"totalTrials":31,"cells":1239},{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1256,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1241,"activeCount":95},[],{"trials":1243,"activeCount":95},[1244],{"nctId":1245,"briefTitle":1246,"status":548,"phases":1247,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":1251,"conditions":1252,"interventions":1254},"NCT05537038","Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers",[83],"2025-06-06","2025-12-08","2023-04-18",120,[1253],"Tuberculosis",[39,1255],"BNT164b1",{"trials":1257,"activeCount":12,"soonestReadout":38},[1258],{"nctId":36,"briefTitle":37,"status":235,"phases":1259,"primaryCompletion":38,"completion":1260,"start":1261,"enrollment":1262,"conditions":1263,"interventions":1264},[83,84],"2027-01","2023-07-31",497,[1253],[39,1255],{"trials":1266,"activeCount":95},[],{"trials":1268,"activeCount":95},[],{"trials":1270,"activeCount":95},[],{"intervention":1255,"totalTrials":31,"cells":1272},{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1281,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1274,"activeCount":95},[],{"trials":1276,"activeCount":95},[1277],{"nctId":1245,"briefTitle":1246,"status":548,"phases":1278,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":1251,"conditions":1279,"interventions":1280},[83],[1253],[39,1255],{"trials":1282,"activeCount":12,"soonestReadout":38},[1283],{"nctId":36,"briefTitle":37,"status":235,"phases":1284,"primaryCompletion":38,"completion":1260,"start":1261,"enrollment":1262,"conditions":1285,"interventions":1286},[83,84],[1253],[39,1255],{"trials":1288,"activeCount":95},[],{"trials":1290,"activeCount":95},[],{"trials":1292,"activeCount":95},[],{"intervention":243,"totalTrials":12,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1296,"activeCount":95},[],{"trials":1298,"activeCount":95},[],{"trials":1300,"activeCount":12,"soonestReadout":67},[1301],{"nctId":65,"briefTitle":66,"status":235,"phases":1302,"primaryCompletion":67,"completion":237,"start":238,"enrollment":239,"conditions":1303,"interventions":1304},[84],[30,241],[68,243,174,175,188,244],{"trials":1306,"activeCount":95},[],{"trials":1308,"activeCount":95},[],{"trials":1310,"activeCount":95},[],{"intervention":244,"totalTrials":12,"cells":1312},{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1323,"PHASE4":1325,"NA":1327},{"trials":1314,"activeCount":95},[],{"trials":1316,"activeCount":95},[],{"trials":1318,"activeCount":12,"soonestReadout":67},[1319],{"nctId":65,"briefTitle":66,"status":235,"phases":1320,"primaryCompletion":67,"completion":237,"start":238,"enrollment":239,"conditions":1321,"interventions":1322},[84],[30,241],[68,243,174,175,188,244],{"trials":1324,"activeCount":95},[],{"trials":1326,"activeCount":95},[],{"trials":1328,"activeCount":95},[],{"intervention":435,"totalTrials":12,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1341,"PHASE4":1343,"NA":1345},{"trials":1332,"activeCount":95},[],{"trials":1334,"activeCount":95},[],{"trials":1336,"activeCount":12,"soonestReadout":428},[1337],{"nctId":425,"briefTitle":426,"status":103,"phases":1338,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":1339,"interventions":1340},[83,84],[23],[148,434,186,435],{"trials":1342,"activeCount":95},[],{"trials":1344,"activeCount":95},[],{"trials":1346,"activeCount":95},[],{"intervention":257,"totalTrials":12,"cells":1348},{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1359,"PHASE4":1361,"NA":1363},{"trials":1350,"activeCount":95},[],{"trials":1352,"activeCount":95},[],{"trials":1354,"activeCount":12,"soonestReadout":129},[1355],{"nctId":246,"briefTitle":247,"status":235,"phases":1356,"primaryCompletion":129,"completion":249,"start":250,"enrollment":251,"conditions":1357,"interventions":1358},[84],[253,254,255],[68,68,257,175,136,188,201,258,259],{"trials":1360,"activeCount":95},[],{"trials":1362,"activeCount":95},[],{"trials":1364,"activeCount":95},[],{"intervention":258,"totalTrials":12,"cells":1366},{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1377,"PHASE4":1379,"NA":1381},{"trials":1368,"activeCount":95},[],{"trials":1370,"activeCount":95},[],{"trials":1372,"activeCount":12,"soonestReadout":129},[1373],{"nctId":246,"briefTitle":247,"status":235,"phases":1374,"primaryCompletion":129,"completion":249,"start":250,"enrollment":251,"conditions":1375,"interventions":1376},[84],[253,254,255],[68,68,257,175,136,188,201,258,259],{"trials":1378,"activeCount":95},[],{"trials":1380,"activeCount":95},[],{"trials":1382,"activeCount":95},[],{"intervention":259,"totalTrials":12,"cells":1384},{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1395,"PHASE4":1397,"NA":1399},{"trials":1386,"activeCount":95},[],{"trials":1388,"activeCount":95},[],{"trials":1390,"activeCount":12,"soonestReadout":129},[1391],{"nctId":246,"briefTitle":247,"status":235,"phases":1392,"primaryCompletion":129,"completion":249,"start":250,"enrollment":251,"conditions":1393,"interventions":1394},[84],[253,254,255],[68,68,257,175,136,188,201,258,259],{"trials":1396,"activeCount":95},[],{"trials":1398,"activeCount":95},[],{"trials":1400,"activeCount":95},[],{"intervention":123,"totalTrials":12,"cells":1402},{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1404,"activeCount":95},[],{"trials":1406,"activeCount":95},[],{"trials":1408,"activeCount":12,"soonestReadout":115},[1409],{"nctId":112,"briefTitle":113,"status":103,"phases":1410,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":1411,"interventions":1412},[84],[120],[90,122,123],{"trials":1414,"activeCount":95},[],{"trials":1416,"activeCount":95},[],{"trials":1418,"activeCount":95},[],{"intervention":1420,"totalTrials":12,"cells":1421},"BNT329",{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1423,"activeCount":95},[],{"trials":1425,"activeCount":95},[],{"trials":1427,"activeCount":12,"soonestReadout":1432},[1428],{"nctId":1429,"briefTitle":1430,"status":103,"phases":1431,"primaryCompletion":1432,"completion":1432,"start":1433,"enrollment":1434,"conditions":1435,"interventions":1437},"NCT07186842","A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9",[83,84],"2030-05","2025-11-18",245,[1436],"Advanced Solid Cancers",[1420,1438],"CA19-9-targeting monoclonal antibody",{"trials":1440,"activeCount":95},[],{"trials":1442,"activeCount":95},[],{"trials":1444,"activeCount":95},[],{"intervention":1438,"totalTrials":12,"cells":1446},{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1457,"PHASE4":1459,"NA":1461},{"trials":1448,"activeCount":95},[],{"trials":1450,"activeCount":95},[],{"trials":1452,"activeCount":12,"soonestReadout":1432},[1453],{"nctId":1429,"briefTitle":1430,"status":103,"phases":1454,"primaryCompletion":1432,"completion":1432,"start":1433,"enrollment":1434,"conditions":1455,"interventions":1456},[83,84],[1436],[1420,1438],{"trials":1458,"activeCount":95},[],{"trials":1460,"activeCount":95},[],{"trials":1462,"activeCount":95},[],{"intervention":1464,"totalTrials":12,"cells":1465},"BNT3214",{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1482,"PHASE4":1484,"NA":1486},{"trials":1467,"activeCount":95},[],{"trials":1469,"activeCount":95},[],{"trials":1471,"activeCount":12,"soonestReadout":1476},[1472],{"nctId":1473,"briefTitle":1474,"status":103,"phases":1475,"primaryCompletion":1476,"completion":1476,"start":1477,"enrollment":1478,"conditions":1479,"interventions":1481},"NCT07455734","Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors",[83,84],"2030-10","2026-03-30",533,[1480],"Advanced Solid Tumor Cancer",[1464],{"trials":1483,"activeCount":95},[],{"trials":1485,"activeCount":95},[],{"trials":1487,"activeCount":95},[],{"intervention":149,"totalTrials":12,"cells":1489},{"EARLY_PHASE1":1490,"PHASE1":1492,"PHASE2":1494,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1491,"activeCount":95},[],{"trials":1493,"activeCount":95},[],{"trials":1495,"activeCount":12,"soonestReadout":142},[1496],{"nctId":139,"briefTitle":140,"status":103,"phases":1497,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":1498,"interventions":1499},[83,84],[26],[148,90,149,150],{"trials":1501,"activeCount":95},[],{"trials":1503,"activeCount":95},[],{"trials":1505,"activeCount":95},[],{"intervention":150,"totalTrials":12,"cells":1507},{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1518,"PHASE4":1520,"NA":1522},{"trials":1509,"activeCount":95},[],{"trials":1511,"activeCount":95},[],{"trials":1513,"activeCount":12,"soonestReadout":142},[1514],{"nctId":139,"briefTitle":140,"status":103,"phases":1515,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":1516,"interventions":1517},[83,84],[26],[148,90,149,150],{"trials":1519,"activeCount":95},[],{"trials":1521,"activeCount":95},[],{"trials":1523,"activeCount":95},[],{"intervention":63,"totalTrials":12,"cells":1525},{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1541,"PHASE4":1543,"NA":1545},{"trials":1527,"activeCount":95},[],{"trials":1529,"activeCount":95},[],{"trials":1531,"activeCount":12,"soonestReadout":62},[1532],{"nctId":60,"briefTitle":61,"status":235,"phases":1533,"primaryCompletion":62,"completion":1534,"start":1535,"enrollment":1536,"conditions":1537,"interventions":1540},[84],"2030-08","2021-03-08",327,[1538,1539],"Colorectal Cancer Stage II","Colorectal Cancer Stage III",[63],{"trials":1542,"activeCount":95},[],{"trials":1544,"activeCount":95},[],{"trials":1546,"activeCount":95},[],{"intervention":1038,"totalTrials":12,"cells":1548},{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1550,"activeCount":95},[],{"trials":1552,"activeCount":95},[],{"trials":1554,"activeCount":12,"soonestReadout":237},[1555],{"nctId":1028,"briefTitle":1029,"status":103,"phases":1556,"primaryCompletion":237,"completion":1031,"start":1032,"enrollment":1033,"conditions":1557,"interventions":1558},[83,84],[253,1035,1036],[1038,434],{"trials":1560,"activeCount":95},[],{"trials":1562,"activeCount":95},[],{"trials":1564,"activeCount":95},[],{"intervention":160,"totalTrials":12,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1568,"activeCount":95},[],{"trials":1570,"activeCount":95},[],{"trials":1572,"activeCount":12,"soonestReadout":155},[1573],{"nctId":152,"briefTitle":153,"status":103,"phases":1574,"primaryCompletion":155,"completion":129,"start":156,"enrollment":157,"conditions":1575,"interventions":1576},[83,84],[26],[160,90],{"trials":1578,"activeCount":95},[],{"trials":1580,"activeCount":95},[],{"trials":1582,"activeCount":95},[],{"intervention":1054,"totalTrials":12,"cells":1584},{"EARLY_PHASE1":1585,"PHASE1":1587,"PHASE2":1589,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1586,"activeCount":95},[],{"trials":1588,"activeCount":95},[],{"trials":1590,"activeCount":12,"soonestReadout":1047},[1591],{"nctId":1044,"briefTitle":1045,"status":103,"phases":1592,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":1050,"conditions":1593,"interventions":1594},[83,84],[1052],[72,434,1054,1055,122],{"trials":1596,"activeCount":95},[],{"trials":1598,"activeCount":95},[],{"trials":1600,"activeCount":95},[],{"intervention":1055,"totalTrials":12,"cells":1602},{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1607,"PHASE3":1613,"PHASE4":1615,"NA":1617},{"trials":1604,"activeCount":95},[],{"trials":1606,"activeCount":95},[],{"trials":1608,"activeCount":12,"soonestReadout":1047},[1609],{"nctId":1044,"briefTitle":1045,"status":103,"phases":1610,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":1050,"conditions":1611,"interventions":1612},[83,84],[1052],[72,434,1054,1055,122],{"trials":1614,"activeCount":95},[],{"trials":1616,"activeCount":95},[],{"trials":1618,"activeCount":95},[],{"intervention":225,"totalTrials":24,"cells":1620},{"EARLY_PHASE1":1621,"PHASE1":1623,"PHASE2":1629,"PHASE3":1655,"PHASE4":1657,"NA":1659},{"trials":1622,"activeCount":95},[],{"trials":1624,"activeCount":12,"soonestReadout":217},[1625],{"nctId":214,"briefTitle":215,"status":103,"phases":1626,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":1627,"interventions":1628},[83],[222],[224,225,110,175,188,226,227,228,229,230,231],{"trials":1630,"activeCount":95},[1631,1645],{"nctId":1632,"briefTitle":1633,"status":548,"phases":1634,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":1639,"interventions":1643},"NCT04526899","A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment",[84],"2024-01-25","2025-11-24","2021-05-19",184,[1640,1641,1642],"Melanoma Stage III","Melanoma Stage IV","Unresectable Melanoma",[1644,225],"BNT111",{"nctId":1646,"briefTitle":1647,"status":263,"phases":1648,"primaryCompletion":1649,"completion":1649,"start":1650,"enrollment":118,"conditions":1651,"interventions":1653},"NCT04382898","PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)",[83,84],"2024-01-23","2019-12-19",[1652],"Prostate Cancer",[1654,225],"BNT112",{"trials":1656,"activeCount":95},[],{"trials":1658,"activeCount":95},[],{"trials":1660,"activeCount":95},[],{"intervention":58,"totalTrials":12,"cells":1662},{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1674,"PHASE3":1676,"PHASE4":1678,"NA":1680},{"trials":1664,"activeCount":95},[],{"trials":1666,"activeCount":12,"soonestReadout":57},[1667],{"nctId":55,"briefTitle":56,"status":235,"phases":1668,"primaryCompletion":57,"completion":57,"start":1669,"enrollment":1670,"conditions":1671,"interventions":1673},[83],"2022-12-08",318,[1672],"Genital Herpes Simplex Type 2",[58],{"trials":1675,"activeCount":95},[],{"trials":1677,"activeCount":95},[],{"trials":1679,"activeCount":95},[],{"trials":1681,"activeCount":95},[],{"intervention":224,"totalTrials":12,"cells":1683},{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1692,"PHASE3":1694,"PHASE4":1696,"NA":1698},{"trials":1685,"activeCount":95},[],{"trials":1687,"activeCount":12,"soonestReadout":217},[1688],{"nctId":214,"briefTitle":215,"status":103,"phases":1689,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":1690,"interventions":1691},[83],[222],[224,225,110,175,188,226,227,228,229,230,231],{"trials":1693,"activeCount":95},[],{"trials":1695,"activeCount":95},[],{"trials":1697,"activeCount":95},[],{"trials":1699,"activeCount":95},[],{"intervention":226,"totalTrials":12,"cells":1701},{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1710,"PHASE3":1712,"PHASE4":1714,"NA":1716},{"trials":1703,"activeCount":95},[],{"trials":1705,"activeCount":12,"soonestReadout":217},[1706],{"nctId":214,"briefTitle":215,"status":103,"phases":1707,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":1708,"interventions":1709},[83],[222],[224,225,110,175,188,226,227,228,229,230,231],{"trials":1711,"activeCount":95},[],{"trials":1713,"activeCount":95},[],{"trials":1715,"activeCount":95},[],{"trials":1717,"activeCount":95},[],{"intervention":227,"totalTrials":12,"cells":1719},{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1728,"PHASE3":1730,"PHASE4":1732,"NA":1734},{"trials":1721,"activeCount":95},[],{"trials":1723,"activeCount":12,"soonestReadout":217},[1724],{"nctId":214,"briefTitle":215,"status":103,"phases":1725,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":1726,"interventions":1727},[83],[222],[224,225,110,175,188,226,227,228,229,230,231],{"trials":1729,"activeCount":95},[],{"trials":1731,"activeCount":95},[],{"trials":1733,"activeCount":95},[],{"trials":1735,"activeCount":95},[],{"intervention":228,"totalTrials":12,"cells":1737},{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1746,"PHASE3":1748,"PHASE4":1750,"NA":1752},{"trials":1739,"activeCount":95},[],{"trials":1741,"activeCount":12,"soonestReadout":217},[1742],{"nctId":214,"briefTitle":215,"status":103,"phases":1743,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":1744,"interventions":1745},[83],[222],[224,225,110,175,188,226,227,228,229,230,231],{"trials":1747,"activeCount":95},[],{"trials":1749,"activeCount":95},[],{"trials":1751,"activeCount":95},[],{"trials":1753,"activeCount":95},[],{"intervention":229,"totalTrials":12,"cells":1755},{"EARLY_PHASE1":1756,"PHASE1":1758,"PHASE2":1764,"PHASE3":1766,"PHASE4":1768,"NA":1770},{"trials":1757,"activeCount":95},[],{"trials":1759,"activeCount":12,"soonestReadout":217},[1760],{"nctId":214,"briefTitle":215,"status":103,"phases":1761,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":1762,"interventions":1763},[83],[222],[224,225,110,175,188,226,227,228,229,230,231],{"trials":1765,"activeCount":95},[],{"trials":1767,"activeCount":95},[],{"trials":1769,"activeCount":95},[],{"trials":1771,"activeCount":95},[],{"intervention":230,"totalTrials":12,"cells":1773},{"EARLY_PHASE1":1774,"PHASE1":1776,"PHASE2":1782,"PHASE3":1784,"PHASE4":1786,"NA":1788},{"trials":1775,"activeCount":95},[],{"trials":1777,"activeCount":12,"soonestReadout":217},[1778],{"nctId":214,"briefTitle":215,"status":103,"phases":1779,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":1780,"interventions":1781},[83],[222],[224,225,110,175,188,226,227,228,229,230,231],{"trials":1783,"activeCount":95},[],{"trials":1785,"activeCount":95},[],{"trials":1787,"activeCount":95},[],{"trials":1789,"activeCount":95},[],{"intervention":231,"totalTrials":12,"cells":1791},{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1800,"PHASE3":1802,"PHASE4":1804,"NA":1806},{"trials":1793,"activeCount":95},[],{"trials":1795,"activeCount":12,"soonestReadout":217},[1796],{"nctId":214,"briefTitle":215,"status":103,"phases":1797,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":1798,"interventions":1799},[83],[222],[224,225,110,175,188,226,227,228,229,230,231],{"trials":1801,"activeCount":95},[],{"trials":1803,"activeCount":95},[],{"trials":1805,"activeCount":95},[],{"trials":1807,"activeCount":95},[],{"intervention":1809,"totalTrials":12,"cells":1810},"BNT317 DL1",{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1830,"PHASE3":1832,"PHASE4":1834,"NA":1836},{"trials":1812,"activeCount":95},[],{"trials":1814,"activeCount":12,"soonestReadout":1819},[1815],{"nctId":1816,"briefTitle":1817,"status":103,"phases":1818,"primaryCompletion":1819,"completion":1819,"start":1820,"enrollment":1821,"conditions":1822,"interventions":1823},"NCT06750185","Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors",[83],"2028-06","2025-01-13",39,[26],[1809,1824,1825,1826,1827,1828,1829],"BNT317 DL2","BNT317 DL3","BNT317 DL4","BNT317 DL5","BNT317 DL6","BNT317 DL7",{"trials":1831,"activeCount":95},[],{"trials":1833,"activeCount":95},[],{"trials":1835,"activeCount":95},[],{"trials":1837,"activeCount":95},[],{"intervention":1824,"totalTrials":12,"cells":1839},{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1848,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1841,"activeCount":95},[],{"trials":1843,"activeCount":12,"soonestReadout":1819},[1844],{"nctId":1816,"briefTitle":1817,"status":103,"phases":1845,"primaryCompletion":1819,"completion":1819,"start":1820,"enrollment":1821,"conditions":1846,"interventions":1847},[83],[26],[1809,1824,1825,1826,1827,1828,1829],{"trials":1849,"activeCount":95},[],{"trials":1851,"activeCount":95},[],{"trials":1853,"activeCount":95},[],{"trials":1855,"activeCount":95},[],{"intervention":1825,"totalTrials":12,"cells":1857},{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1866,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1859,"activeCount":95},[],{"trials":1861,"activeCount":12,"soonestReadout":1819},[1862],{"nctId":1816,"briefTitle":1817,"status":103,"phases":1863,"primaryCompletion":1819,"completion":1819,"start":1820,"enrollment":1821,"conditions":1864,"interventions":1865},[83],[26],[1809,1824,1825,1826,1827,1828,1829],{"trials":1867,"activeCount":95},[],{"trials":1869,"activeCount":95},[],{"trials":1871,"activeCount":95},[],{"trials":1873,"activeCount":95},[],{"intervention":1826,"totalTrials":12,"cells":1875},{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1884,"PHASE3":1886,"PHASE4":1888,"NA":1890},{"trials":1877,"activeCount":95},[],{"trials":1879,"activeCount":12,"soonestReadout":1819},[1880],{"nctId":1816,"briefTitle":1817,"status":103,"phases":1881,"primaryCompletion":1819,"completion":1819,"start":1820,"enrollment":1821,"conditions":1882,"interventions":1883},[83],[26],[1809,1824,1825,1826,1827,1828,1829],{"trials":1885,"activeCount":95},[],{"trials":1887,"activeCount":95},[],{"trials":1889,"activeCount":95},[],{"trials":1891,"activeCount":95},[],{"intervention":1827,"totalTrials":12,"cells":1893},{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1902,"PHASE3":1904,"PHASE4":1906,"NA":1908},{"trials":1895,"activeCount":95},[],{"trials":1897,"activeCount":12,"soonestReadout":1819},[1898],{"nctId":1816,"briefTitle":1817,"status":103,"phases":1899,"primaryCompletion":1819,"completion":1819,"start":1820,"enrollment":1821,"conditions":1900,"interventions":1901},[83],[26],[1809,1824,1825,1826,1827,1828,1829],{"trials":1903,"activeCount":95},[],{"trials":1905,"activeCount":95},[],{"trials":1907,"activeCount":95},[],{"trials":1909,"activeCount":95},[],{"intervention":1828,"totalTrials":12,"cells":1911},{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1913,"activeCount":95},[],{"trials":1915,"activeCount":12,"soonestReadout":1819},[1916],{"nctId":1816,"briefTitle":1817,"status":103,"phases":1917,"primaryCompletion":1819,"completion":1819,"start":1820,"enrollment":1821,"conditions":1918,"interventions":1919},[83],[26],[1809,1824,1825,1826,1827,1828,1829],{"trials":1921,"activeCount":95},[],{"trials":1923,"activeCount":95},[],{"trials":1925,"activeCount":95},[],{"trials":1927,"activeCount":95},[],{"intervention":1829,"totalTrials":12,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1931,"activeCount":95},[],{"trials":1933,"activeCount":12,"soonestReadout":1819},[1934],{"nctId":1816,"briefTitle":1817,"status":103,"phases":1935,"primaryCompletion":1819,"completion":1819,"start":1820,"enrollment":1821,"conditions":1936,"interventions":1937},[83],[26],[1809,1824,1825,1826,1827,1828,1829],{"trials":1939,"activeCount":95},[],{"trials":1941,"activeCount":95},[],{"trials":1943,"activeCount":95},[],{"trials":1945,"activeCount":95},[],{"intervention":80,"totalTrials":12,"cells":1947},{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1959,"PHASE3":1961,"PHASE4":1963,"NA":1965},{"trials":1949,"activeCount":95},[],{"trials":1951,"activeCount":12,"soonestReadout":67},[1952],{"nctId":78,"briefTitle":79,"status":103,"phases":1953,"primaryCompletion":67,"completion":67,"start":1954,"enrollment":1955,"conditions":1956,"interventions":1958},[83],"2026-02-09",61,[1957],"HIV -1 Infection",[80,80],{"trials":1960,"activeCount":95},[],{"trials":1962,"activeCount":95},[],{"trials":1964,"activeCount":95},[],{"trials":1966,"activeCount":95},[],{"intervention":1968,"totalTrials":24,"cells":1969},"Investigational Influenza Vaccine",{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":2004,"PHASE4":2019,"NA":2021},{"trials":1971,"activeCount":95},[],{"trials":1973,"activeCount":95},[],{"trials":1975,"activeCount":95},[1976,1990],{"nctId":1977,"briefTitle":1978,"status":548,"phases":1979,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":1983,"interventions":1985},"NCT06683352","A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People",[83,84],"2025-07-15","2024-11-11",1353,[1984,15],"Influenza,Human",[1968,1986,1987,1988,1989],"COVID-19 Vaccine","Influenza and COVID Combination Vaccine","Licensed Influenza Vaccine 1","Licensed Influenza Vaccine 2",{"nctId":1991,"briefTitle":1992,"status":548,"phases":1993,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":1996,"conditions":1997,"interventions":1999},"NCT06821061","A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People",[83,84],"2025-12-17","2025-02-10",2650,[33,1998],"COVID-19 (Coronavirus Disease 2019)",[1968,2000,2001,1988,1989,2002,2003],"Investigational COVID-19 Vaccine","Investigational Influenza and COVID-19 Combination Vaccine","Licensed Influenza Vaccine 3","Licensed COVID-19 Vaccine",{"trials":2005,"activeCount":95},[2006],{"nctId":2007,"briefTitle":2008,"status":548,"phases":2009,"primaryCompletion":2010,"completion":2010,"start":2011,"enrollment":2012,"conditions":2013,"interventions":2014},"NCT06178991","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.",[85],"2024-11-26","2023-12-20",8795,[33,15],[2015,2016,1986,2017,2018],"Influenza and COVID-19 Combination A","Licensed influenza vaccine","Influenza and COVID-19 Combination B","Investigational influenza vaccine",{"trials":2020,"activeCount":95},[],{"trials":2022,"activeCount":95},[],{"intervention":598,"totalTrials":24,"cells":2024},{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2039,"PHASE3":2045,"PHASE4":2051,"NA":2053},{"trials":2026,"activeCount":95},[],{"trials":2028,"activeCount":95},[2029],{"nctId":2030,"briefTitle":2031,"status":548,"phases":2032,"primaryCompletion":2033,"completion":2034,"start":2035,"enrollment":2036,"conditions":2037,"interventions":2038},"NCT04523571","Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects",[83],"2020-09-30","2021-08-10","2020-07-28",144,[609],[598],{"trials":2040,"activeCount":95},[2041],{"nctId":582,"briefTitle":583,"status":548,"phases":2042,"primaryCompletion":585,"completion":586,"start":587,"enrollment":588,"conditions":2043,"interventions":2044},[83,84],[590,591,592,593,594,595],[597,598,49,599],{"trials":2046,"activeCount":95},[2047],{"nctId":644,"briefTitle":645,"status":548,"phases":2048,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":2049,"interventions":2050},[84,85],[17,15],[598,49,652],{"trials":2052,"activeCount":95},[],{"trials":2054,"activeCount":95},[],{"intervention":1986,"totalTrials":31,"cells":2056},{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2067,"PHASE4":2073,"NA":2075},{"trials":2058,"activeCount":95},[],{"trials":2060,"activeCount":95},[],{"trials":2062,"activeCount":95},[2063],{"nctId":1977,"briefTitle":1978,"status":548,"phases":2064,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":2065,"interventions":2066},[83,84],[1984,15],[1968,1986,1987,1988,1989],{"trials":2068,"activeCount":95},[2069],{"nctId":2007,"briefTitle":2008,"status":548,"phases":2070,"primaryCompletion":2010,"completion":2010,"start":2011,"enrollment":2012,"conditions":2071,"interventions":2072},[85],[33,15],[2015,2016,1986,2017,2018],{"trials":2074,"activeCount":95},[],{"trials":2076,"activeCount":95},[],{"intervention":2015,"totalTrials":12,"cells":2078},{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2083,"PHASE3":2085,"PHASE4":2091,"NA":2093},{"trials":2080,"activeCount":95},[],{"trials":2082,"activeCount":95},[],{"trials":2084,"activeCount":95},[],{"trials":2086,"activeCount":95},[2087],{"nctId":2007,"briefTitle":2008,"status":548,"phases":2088,"primaryCompletion":2010,"completion":2010,"start":2011,"enrollment":2012,"conditions":2089,"interventions":2090},[85],[33,15],[2015,2016,1986,2017,2018],{"trials":2092,"activeCount":95},[],{"trials":2094,"activeCount":95},[],{"intervention":2016,"totalTrials":12,"cells":2096},{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2109,"NA":2111},{"trials":2098,"activeCount":95},[],{"trials":2100,"activeCount":95},[],{"trials":2102,"activeCount":95},[],{"trials":2104,"activeCount":95},[2105],{"nctId":2007,"briefTitle":2008,"status":548,"phases":2106,"primaryCompletion":2010,"completion":2010,"start":2011,"enrollment":2012,"conditions":2107,"interventions":2108},[85],[33,15],[2015,2016,1986,2017,2018],{"trials":2110,"activeCount":95},[],{"trials":2112,"activeCount":95},[],{"intervention":2017,"totalTrials":12,"cells":2114},{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2119,"PHASE3":2121,"PHASE4":2127,"NA":2129},{"trials":2116,"activeCount":95},[],{"trials":2118,"activeCount":95},[],{"trials":2120,"activeCount":95},[],{"trials":2122,"activeCount":95},[2123],{"nctId":2007,"briefTitle":2008,"status":548,"phases":2124,"primaryCompletion":2010,"completion":2010,"start":2011,"enrollment":2012,"conditions":2125,"interventions":2126},[85],[33,15],[2015,2016,1986,2017,2018],{"trials":2128,"activeCount":95},[],{"trials":2130,"activeCount":95},[],{"intervention":642,"totalTrials":12,"cells":2132},{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2145,"NA":2147},{"trials":2134,"activeCount":95},[],{"trials":2136,"activeCount":95},[],{"trials":2138,"activeCount":95},[],{"trials":2140,"activeCount":95},[2141],{"nctId":634,"briefTitle":635,"status":548,"phases":2142,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":2143,"interventions":2144},[85],[17,15],[49,642],{"trials":2146,"activeCount":95},[],{"trials":2148,"activeCount":95},[],{"intervention":652,"totalTrials":12,"cells":2150},{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2157,"PHASE4":2163,"NA":2165},{"trials":2152,"activeCount":95},[],{"trials":2154,"activeCount":95},[],{"trials":2156,"activeCount":95},[],{"trials":2158,"activeCount":95},[2159],{"nctId":644,"briefTitle":645,"status":548,"phases":2160,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":2161,"interventions":2162},[84,85],[17,15],[598,49,652],{"trials":2164,"activeCount":95},[],{"trials":2166,"activeCount":95},[],{"intervention":671,"totalTrials":12,"cells":2168},{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2175,"PHASE4":2181,"NA":2183},{"trials":2170,"activeCount":95},[],{"trials":2172,"activeCount":95},[],{"trials":2174,"activeCount":95},[],{"trials":2176,"activeCount":95},[2177],{"nctId":663,"briefTitle":664,"status":548,"phases":2178,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":2179,"interventions":2180},[85],[17,15],[49,671],{"trials":2182,"activeCount":95},[],{"trials":2184,"activeCount":95},[],{"intervention":2186,"totalTrials":12,"cells":2187},"BNT162b5 Bivalent",{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2209,"NA":2211},{"trials":2189,"activeCount":95},[],{"trials":2191,"activeCount":95},[],{"trials":2193,"activeCount":95},[],{"trials":2195,"activeCount":95},[2196],{"nctId":2197,"briefTitle":2198,"status":548,"phases":2199,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":2202,"conditions":2203,"interventions":2204},"NCT05472038","A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals",[84,85],"2024-03-26","2022-07-26",1453,[17,15],[2186,2205,2205,2186,2206,2207,2208],"BNT162b2 Bivalent","BNT162b6 Bivalent","BNT162b7 Bivalent","BNT162b7 Monovalent",{"trials":2210,"activeCount":95},[],{"trials":2212,"activeCount":95},[],{"intervention":2205,"totalTrials":12,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2221,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":95},[],{"trials":2218,"activeCount":95},[],{"trials":2220,"activeCount":95},[],{"trials":2222,"activeCount":95},[2223],{"nctId":2197,"briefTitle":2198,"status":548,"phases":2224,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":2202,"conditions":2225,"interventions":2226},[84,85],[17,15],[2186,2205,2205,2186,2206,2207,2208],{"trials":2228,"activeCount":95},[],{"trials":2230,"activeCount":95},[],{"intervention":2206,"totalTrials":12,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2239,"PHASE4":2245,"NA":2247},{"trials":2234,"activeCount":95},[],{"trials":2236,"activeCount":95},[],{"trials":2238,"activeCount":95},[],{"trials":2240,"activeCount":95},[2241],{"nctId":2197,"briefTitle":2198,"status":548,"phases":2242,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":2202,"conditions":2243,"interventions":2244},[84,85],[17,15],[2186,2205,2205,2186,2206,2207,2208],{"trials":2246,"activeCount":95},[],{"trials":2248,"activeCount":95},[],{"intervention":2207,"totalTrials":12,"cells":2250},{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2255,"PHASE3":2257,"PHASE4":2263,"NA":2265},{"trials":2252,"activeCount":95},[],{"trials":2254,"activeCount":95},[],{"trials":2256,"activeCount":95},[],{"trials":2258,"activeCount":95},[2259],{"nctId":2197,"briefTitle":2198,"status":548,"phases":2260,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":2202,"conditions":2261,"interventions":2262},[84,85],[17,15],[2186,2205,2205,2186,2206,2207,2208],{"trials":2264,"activeCount":95},[],{"trials":2266,"activeCount":95},[],{"intervention":2208,"totalTrials":12,"cells":2268},{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2281,"NA":2283},{"trials":2270,"activeCount":95},[],{"trials":2272,"activeCount":95},[],{"trials":2274,"activeCount":95},[],{"trials":2276,"activeCount":95},[2277],{"nctId":2197,"briefTitle":2198,"status":548,"phases":2278,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":2202,"conditions":2279,"interventions":2280},[84,85],[17,15],[2186,2205,2205,2186,2206,2207,2208],{"trials":2282,"activeCount":95},[],{"trials":2284,"activeCount":95},[],{"intervention":695,"totalTrials":12,"cells":2286},{"EARLY_PHASE1":2287,"PHASE1":2289,"PHASE2":2291,"PHASE3":2293,"PHASE4":2299,"NA":2301},{"trials":2288,"activeCount":95},[],{"trials":2290,"activeCount":95},[],{"trials":2292,"activeCount":95},[],{"trials":2294,"activeCount":95},[2295],{"nctId":687,"briefTitle":688,"status":548,"phases":2296,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":2297,"interventions":2298},[85],[17,15],[49,695,696,697],{"trials":2300,"activeCount":95},[],{"trials":2302,"activeCount":95},[],{"intervention":696,"totalTrials":12,"cells":2304},{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2309,"PHASE3":2311,"PHASE4":2317,"NA":2319},{"trials":2306,"activeCount":95},[],{"trials":2308,"activeCount":95},[],{"trials":2310,"activeCount":95},[],{"trials":2312,"activeCount":95},[2313],{"nctId":687,"briefTitle":688,"status":548,"phases":2314,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":2315,"interventions":2316},[85],[17,15],[49,695,696,697],{"trials":2318,"activeCount":95},[],{"trials":2320,"activeCount":95},[],{"intervention":697,"totalTrials":12,"cells":2322},{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2329,"PHASE4":2335,"NA":2337},{"trials":2324,"activeCount":95},[],{"trials":2326,"activeCount":95},[],{"trials":2328,"activeCount":95},[],{"trials":2330,"activeCount":95},[2331],{"nctId":687,"briefTitle":688,"status":548,"phases":2332,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":2333,"interventions":2334},[85],[17,15],[49,695,696,697],{"trials":2336,"activeCount":95},[],{"trials":2338,"activeCount":95},[],{"intervention":2340,"totalTrials":12,"cells":2341},"Biological\u002FVaccine: BNT162b2 10mcg",{"EARLY_PHASE1":2342,"PHASE1":2344,"PHASE2":2346,"PHASE3":2348,"PHASE4":2363,"NA":2365},{"trials":2343,"activeCount":95},[],{"trials":2345,"activeCount":95},[],{"trials":2347,"activeCount":95},[],{"trials":2349,"activeCount":95},[2350],{"nctId":2351,"briefTitle":2352,"status":548,"phases":2353,"primaryCompletion":551,"completion":2354,"start":2355,"enrollment":2356,"conditions":2357,"interventions":2359},"NCT04816643","Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children",[85],"2023-12-08","2021-03-24",11837,[2358],"SARS-CoV-2 Infection, COVID-19",[2340,2360,2361,2362],"BNT162b2 20mcg","BNT162b2 30mcg","Biological\u002FVaccine: BNT162b2 3mcg",{"trials":2364,"activeCount":95},[],{"trials":2366,"activeCount":95},[],{"intervention":2360,"totalTrials":12,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2375,"PHASE4":2381,"NA":2383},{"trials":2370,"activeCount":95},[],{"trials":2372,"activeCount":95},[],{"trials":2374,"activeCount":95},[],{"trials":2376,"activeCount":95},[2377],{"nctId":2351,"briefTitle":2352,"status":548,"phases":2378,"primaryCompletion":551,"completion":2354,"start":2355,"enrollment":2356,"conditions":2379,"interventions":2380},[85],[2358],[2340,2360,2361,2362],{"trials":2382,"activeCount":95},[],{"trials":2384,"activeCount":95},[],{"intervention":2361,"totalTrials":12,"cells":2386},{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2399,"NA":2401},{"trials":2388,"activeCount":95},[],{"trials":2390,"activeCount":95},[],{"trials":2392,"activeCount":95},[],{"trials":2394,"activeCount":95},[2395],{"nctId":2351,"briefTitle":2352,"status":548,"phases":2396,"primaryCompletion":551,"completion":2354,"start":2355,"enrollment":2356,"conditions":2397,"interventions":2398},[85],[2358],[2340,2360,2361,2362],{"trials":2400,"activeCount":95},[],{"trials":2402,"activeCount":95},[],{"intervention":2362,"totalTrials":12,"cells":2404},{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2409,"PHASE3":2411,"PHASE4":2417,"NA":2419},{"trials":2406,"activeCount":95},[],{"trials":2408,"activeCount":95},[],{"trials":2410,"activeCount":95},[],{"trials":2412,"activeCount":95},[2413],{"nctId":2351,"briefTitle":2352,"status":548,"phases":2414,"primaryCompletion":551,"completion":2354,"start":2355,"enrollment":2356,"conditions":2415,"interventions":2416},[85],[2358],[2340,2360,2361,2362],{"trials":2418,"activeCount":95},[],{"trials":2420,"activeCount":95},[],{"intervention":1988,"totalTrials":31,"cells":2422},{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2437,"PHASE4":2439,"NA":2441},{"trials":2424,"activeCount":95},[],{"trials":2426,"activeCount":95},[],{"trials":2428,"activeCount":95},[2429,2433],{"nctId":1977,"briefTitle":1978,"status":548,"phases":2430,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":2431,"interventions":2432},[83,84],[1984,15],[1968,1986,1987,1988,1989],{"nctId":1991,"briefTitle":1992,"status":548,"phases":2434,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":1996,"conditions":2435,"interventions":2436},[83,84],[33,1998],[1968,2000,2001,1988,1989,2002,2003],{"trials":2438,"activeCount":95},[],{"trials":2440,"activeCount":95},[],{"trials":2442,"activeCount":95},[],{"intervention":1989,"totalTrials":31,"cells":2444},{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2459,"PHASE4":2461,"NA":2463},{"trials":2446,"activeCount":95},[],{"trials":2448,"activeCount":95},[],{"trials":2450,"activeCount":95},[2451,2455],{"nctId":1977,"briefTitle":1978,"status":548,"phases":2452,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":2453,"interventions":2454},[83,84],[1984,15],[1968,1986,1987,1988,1989],{"nctId":1991,"briefTitle":1992,"status":548,"phases":2456,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":1996,"conditions":2457,"interventions":2458},[83,84],[33,1998],[1968,2000,2001,1988,1989,2002,2003],{"trials":2460,"activeCount":95},[],{"trials":2462,"activeCount":95},[],{"trials":2464,"activeCount":95},[],{"intervention":2466,"totalTrials":12,"cells":2467},"BNT162b3",{"EARLY_PHASE1":2468,"PHASE1":2470,"PHASE2":2472,"PHASE3":2485,"PHASE4":2487,"NA":2489},{"trials":2469,"activeCount":95},[],{"trials":2471,"activeCount":95},[],{"trials":2473,"activeCount":95},[2474],{"nctId":2475,"briefTitle":2476,"status":548,"phases":2477,"primaryCompletion":2478,"completion":2479,"start":2480,"enrollment":1219,"conditions":2481,"interventions":2484},"NCT04537949","A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults",[83,84],"2021-03-12","2022-02-07","2020-09-09",[2482,2483],"Covid-19","Protection Against COVID-19",[2466],{"trials":2486,"activeCount":95},[],{"trials":2488,"activeCount":95},[],{"trials":2490,"activeCount":95},[],{"intervention":2492,"totalTrials":12,"cells":2493},"CLDN6 CAR-T",{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2511,"PHASE4":2513,"NA":2515},{"trials":2495,"activeCount":95},[],{"trials":2497,"activeCount":95},[],{"trials":2499,"activeCount":95},[2500],{"nctId":2501,"briefTitle":2502,"status":742,"phases":2503,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":95,"conditions":2506,"interventions":2509},"NCT06940804","A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm",[84],"2042-06","2025-07",[2507,2508],"Testicular Germ Cell Tumor","Extragonadal Germ Cell Tumor",[2492,2510],"CLDN6 RNA-LPX",{"trials":2512,"activeCount":95},[],{"trials":2514,"activeCount":95},[],{"trials":2516,"activeCount":95},[],{"intervention":2510,"totalTrials":12,"cells":2518},{"EARLY_PHASE1":2519,"PHASE1":2521,"PHASE2":2523,"PHASE3":2529,"PHASE4":2531,"NA":2533},{"trials":2520,"activeCount":95},[],{"trials":2522,"activeCount":95},[],{"trials":2524,"activeCount":95},[2525],{"nctId":2501,"briefTitle":2502,"status":742,"phases":2526,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":95,"conditions":2527,"interventions":2528},[84],[2507,2508],[2492,2510],{"trials":2530,"activeCount":95},[],{"trials":2532,"activeCount":95},[],{"trials":2534,"activeCount":95},[],{"intervention":1644,"totalTrials":12,"cells":2536},{"EARLY_PHASE1":2537,"PHASE1":2539,"PHASE2":2541,"PHASE3":2547,"PHASE4":2549,"NA":2551},{"trials":2538,"activeCount":95},[],{"trials":2540,"activeCount":95},[],{"trials":2542,"activeCount":95},[2543],{"nctId":1632,"briefTitle":1633,"status":548,"phases":2544,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":2545,"interventions":2546},[84],[1640,1641,1642],[1644,225],{"trials":2548,"activeCount":95},[],{"trials":2550,"activeCount":95},[],{"trials":2552,"activeCount":95},[],{"intervention":401,"totalTrials":12,"cells":2554},{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2565,"PHASE4":2567,"NA":2569},{"trials":2556,"activeCount":95},[],{"trials":2558,"activeCount":95},[],{"trials":2560,"activeCount":95},[2561],{"nctId":386,"briefTitle":387,"status":263,"phases":2562,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":2563,"interventions":2564},[83,84],[20,393,394,395,396,397,398,399],[401,135,136],{"trials":2566,"activeCount":95},[],{"trials":2568,"activeCount":95},[],{"trials":2570,"activeCount":95},[],{"intervention":558,"totalTrials":12,"cells":2572},{"EARLY_PHASE1":2573,"PHASE1":2575,"PHASE2":2577,"PHASE3":2583,"PHASE4":2585,"NA":2587},{"trials":2574,"activeCount":95},[],{"trials":2576,"activeCount":95},[],{"trials":2578,"activeCount":95},[2579],{"nctId":546,"briefTitle":547,"status":548,"phases":2580,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":2581,"interventions":2582},[84],[17,15,555,556],[49,558,559,559,559],{"trials":2584,"activeCount":95},[],{"trials":2586,"activeCount":95},[],{"trials":2588,"activeCount":95},[],{"intervention":559,"totalTrials":12,"cells":2590},{"EARLY_PHASE1":2591,"PHASE1":2593,"PHASE2":2595,"PHASE3":2601,"PHASE4":2603,"NA":2605},{"trials":2592,"activeCount":95},[],{"trials":2594,"activeCount":95},[],{"trials":2596,"activeCount":95},[2597],{"nctId":546,"briefTitle":547,"status":548,"phases":2598,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":2599,"interventions":2600},[84],[17,15,555,556],[49,558,559,559,559],{"trials":2602,"activeCount":95},[],{"trials":2604,"activeCount":95},[],{"trials":2606,"activeCount":95},[],{"intervention":1195,"totalTrials":12,"cells":2608},{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2619,"PHASE4":2621,"NA":2623},{"trials":2610,"activeCount":95},[],{"trials":2612,"activeCount":95},[],{"trials":2614,"activeCount":95},[2615],{"nctId":1188,"briefTitle":1189,"status":263,"phases":2616,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":12,"conditions":2617,"interventions":2618},[83,84],[396],[1195,1196,137,1197],{"trials":2620,"activeCount":95},[],{"trials":2622,"activeCount":95},[],{"trials":2624,"activeCount":95},[],{"intervention":1196,"totalTrials":12,"cells":2626},{"EARLY_PHASE1":2627,"PHASE1":2629,"PHASE2":2631,"PHASE3":2637,"PHASE4":2639,"NA":2641},{"trials":2628,"activeCount":95},[],{"trials":2630,"activeCount":95},[],{"trials":2632,"activeCount":95},[2633],{"nctId":1188,"briefTitle":1189,"status":263,"phases":2634,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":12,"conditions":2635,"interventions":2636},[83,84],[396],[1195,1196,137,1197],{"trials":2638,"activeCount":95},[],{"trials":2640,"activeCount":95},[],{"trials":2642,"activeCount":95},[],{"intervention":1197,"totalTrials":12,"cells":2644},{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2649,"PHASE3":2655,"PHASE4":2657,"NA":2659},{"trials":2646,"activeCount":95},[],{"trials":2648,"activeCount":95},[],{"trials":2650,"activeCount":95},[2651],{"nctId":1188,"briefTitle":1189,"status":263,"phases":2652,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":12,"conditions":2653,"interventions":2654},[83,84],[396],[1195,1196,137,1197],{"trials":2656,"activeCount":95},[],{"trials":2658,"activeCount":95},[],{"trials":2660,"activeCount":95},[],{"intervention":2662,"totalTrials":12,"cells":2663},"BNT151",{"EARLY_PHASE1":2664,"PHASE1":2666,"PHASE2":2668,"PHASE3":2679,"PHASE4":2681,"NA":2683},{"trials":2665,"activeCount":95},[],{"trials":2667,"activeCount":95},[],{"trials":2669,"activeCount":95},[2670],{"nctId":2671,"briefTitle":2672,"status":263,"phases":2673,"primaryCompletion":2674,"completion":2674,"start":2675,"enrollment":2676,"conditions":2677,"interventions":2678},"NCT04455620","BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors",[83,84],"2024-05-28","2021-01-26",49,[20],[2662],{"trials":2680,"activeCount":95},[],{"trials":2682,"activeCount":95},[],{"trials":2684,"activeCount":95},[],{"intervention":1654,"totalTrials":12,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2697,"PHASE4":2699,"NA":2701},{"trials":2688,"activeCount":95},[],{"trials":2690,"activeCount":95},[],{"trials":2692,"activeCount":95},[2693],{"nctId":1646,"briefTitle":1647,"status":263,"phases":2694,"primaryCompletion":1649,"completion":1649,"start":1650,"enrollment":118,"conditions":2695,"interventions":2696},[83,84],[1652],[1654,225],{"trials":2698,"activeCount":95},[],{"trials":2700,"activeCount":95},[],{"trials":2702,"activeCount":95},[],{"intervention":580,"totalTrials":12,"cells":2704},{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2715,"PHASE4":2717,"NA":2719},{"trials":2706,"activeCount":95},[],{"trials":2708,"activeCount":95},[],{"trials":2710,"activeCount":95},[2711],{"nctId":571,"briefTitle":572,"status":548,"phases":2712,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":2713,"interventions":2714},[84],[15,17],[580,49],{"trials":2716,"activeCount":95},[],{"trials":2718,"activeCount":95},[],{"trials":2720,"activeCount":95},[],{"intervention":597,"totalTrials":12,"cells":2722},{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2724,"activeCount":95},[],{"trials":2726,"activeCount":95},[],{"trials":2728,"activeCount":95},[2729],{"nctId":582,"briefTitle":583,"status":548,"phases":2730,"primaryCompletion":585,"completion":586,"start":587,"enrollment":588,"conditions":2731,"interventions":2732},[83,84],[590,591,592,593,594,595],[597,598,49,599],{"trials":2734,"activeCount":95},[],{"trials":2736,"activeCount":95},[],{"trials":2738,"activeCount":95},[],{"intervention":599,"totalTrials":12,"cells":2740},{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2745,"PHASE3":2751,"PHASE4":2753,"NA":2755},{"trials":2742,"activeCount":95},[],{"trials":2744,"activeCount":95},[],{"trials":2746,"activeCount":95},[2747],{"nctId":582,"briefTitle":583,"status":548,"phases":2748,"primaryCompletion":585,"completion":586,"start":587,"enrollment":588,"conditions":2749,"interventions":2750},[83,84],[590,591,592,593,594,595],[597,598,49,599],{"trials":2752,"activeCount":95},[],{"trials":2754,"activeCount":95},[],{"trials":2756,"activeCount":95},[],{"intervention":272,"totalTrials":12,"cells":2758},{"EARLY_PHASE1":2759,"PHASE1":2761,"PHASE2":2763,"PHASE3":2769,"PHASE4":2771,"NA":2773},{"trials":2760,"activeCount":95},[],{"trials":2762,"activeCount":95},[],{"trials":2764,"activeCount":95},[2765],{"nctId":261,"briefTitle":262,"status":263,"phases":2766,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":2767,"interventions":2768},[83,84],[20,270],[272,173,175,174],{"trials":2770,"activeCount":95},[],{"trials":2772,"activeCount":95},[],{"trials":2774,"activeCount":95},[],{"intervention":2776,"totalTrials":12,"cells":2777},"BNT142",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2793,"PHASE4":2795,"NA":2797},{"trials":2779,"activeCount":95},[],{"trials":2781,"activeCount":95},[],{"trials":2783,"activeCount":95},[2784],{"nctId":2785,"briefTitle":2786,"status":263,"phases":2787,"primaryCompletion":2788,"completion":2788,"start":2789,"enrollment":2790,"conditions":2791,"interventions":2792},"NCT05262530","Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors",[83,84],"2025-12-22","2022-03-22",73,[20],[2776],{"trials":2794,"activeCount":95},[],{"trials":2796,"activeCount":95},[],{"trials":2798,"activeCount":95},[],{"intervention":1987,"totalTrials":12,"cells":2800},{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2811,"PHASE4":2813,"NA":2815},{"trials":2802,"activeCount":95},[],{"trials":2804,"activeCount":95},[],{"trials":2806,"activeCount":95},[2807],{"nctId":1977,"briefTitle":1978,"status":548,"phases":2808,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":2809,"interventions":2810},[83,84],[1984,15],[1968,1986,1987,1988,1989],{"trials":2812,"activeCount":95},[],{"trials":2814,"activeCount":95},[],{"trials":2816,"activeCount":95},[],{"intervention":2818,"totalTrials":12,"cells":2819},"bivalent BNT162b2",{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2824,"PHASE3":2840,"PHASE4":2842,"NA":2844},{"trials":2821,"activeCount":95},[],{"trials":2823,"activeCount":95},[],{"trials":2825,"activeCount":95},[2826],{"nctId":2827,"briefTitle":2828,"status":548,"phases":2829,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":2832,"conditions":2833,"interventions":2835},"NCT05596734","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza",[84],"2023-12-28","2022-10-28",1019,[2834,15],"Influenza, Human",[2818,2836,2837,2838,2839],"qIRV","QIV","bIRV","tIRV",{"trials":2841,"activeCount":95},[],{"trials":2843,"activeCount":95},[],{"trials":2845,"activeCount":95},[],{"intervention":2836,"totalTrials":12,"cells":2847},{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2852,"PHASE3":2858,"PHASE4":2860,"NA":2862},{"trials":2849,"activeCount":95},[],{"trials":2851,"activeCount":95},[],{"trials":2853,"activeCount":95},[2854],{"nctId":2827,"briefTitle":2828,"status":548,"phases":2855,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":2832,"conditions":2856,"interventions":2857},[84],[2834,15],[2818,2836,2837,2838,2839],{"trials":2859,"activeCount":95},[],{"trials":2861,"activeCount":95},[],{"trials":2863,"activeCount":95},[],{"intervention":2837,"totalTrials":12,"cells":2865},{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2870,"PHASE3":2876,"PHASE4":2878,"NA":2880},{"trials":2867,"activeCount":95},[],{"trials":2869,"activeCount":95},[],{"trials":2871,"activeCount":95},[2872],{"nctId":2827,"briefTitle":2828,"status":548,"phases":2873,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":2832,"conditions":2874,"interventions":2875},[84],[2834,15],[2818,2836,2837,2838,2839],{"trials":2877,"activeCount":95},[],{"trials":2879,"activeCount":95},[],{"trials":2881,"activeCount":95},[],{"intervention":2838,"totalTrials":12,"cells":2883},{"EARLY_PHASE1":2884,"PHASE1":2886,"PHASE2":2888,"PHASE3":2894,"PHASE4":2896,"NA":2898},{"trials":2885,"activeCount":95},[],{"trials":2887,"activeCount":95},[],{"trials":2889,"activeCount":95},[2890],{"nctId":2827,"briefTitle":2828,"status":548,"phases":2891,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":2832,"conditions":2892,"interventions":2893},[84],[2834,15],[2818,2836,2837,2838,2839],{"trials":2895,"activeCount":95},[],{"trials":2897,"activeCount":95},[],{"trials":2899,"activeCount":95},[],{"intervention":2839,"totalTrials":12,"cells":2901},{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2912,"PHASE4":2914,"NA":2916},{"trials":2903,"activeCount":95},[],{"trials":2905,"activeCount":95},[],{"trials":2907,"activeCount":95},[2908],{"nctId":2827,"briefTitle":2828,"status":548,"phases":2909,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":2832,"conditions":2910,"interventions":2911},[84],[2834,15],[2818,2836,2837,2838,2839],{"trials":2913,"activeCount":95},[],{"trials":2915,"activeCount":95},[],{"trials":2917,"activeCount":95},[],{"intervention":2919,"totalTrials":12,"cells":2920},"BNT165e",{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2938,"PHASE4":2940,"NA":2942},{"trials":2922,"activeCount":95},[],{"trials":2924,"activeCount":95},[],{"trials":2926,"activeCount":95},[2927],{"nctId":2928,"briefTitle":2929,"status":548,"phases":2930,"primaryCompletion":2931,"completion":2932,"start":2933,"enrollment":2934,"conditions":2935,"interventions":2937},"NCT06069544","A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria",[83,84],"2025-05-28","2026-03-20","2023-11-13",163,[2936],"Malaria",[2919],{"trials":2939,"activeCount":95},[],{"trials":2941,"activeCount":95},[],{"trials":2943,"activeCount":95},[],{"intervention":2000,"totalTrials":12,"cells":2945},{"EARLY_PHASE1":2946,"PHASE1":2948,"PHASE2":2950,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2947,"activeCount":95},[],{"trials":2949,"activeCount":95},[],{"trials":2951,"activeCount":95},[2952],{"nctId":1991,"briefTitle":1992,"status":548,"phases":2953,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":1996,"conditions":2954,"interventions":2955},[83,84],[33,1998],[1968,2000,2001,1988,1989,2002,2003],{"trials":2957,"activeCount":95},[],{"trials":2959,"activeCount":95},[],{"trials":2961,"activeCount":95},[],{"intervention":2001,"totalTrials":12,"cells":2963},{"EARLY_PHASE1":2964,"PHASE1":2966,"PHASE2":2968,"PHASE3":2974,"PHASE4":2976,"NA":2978},{"trials":2965,"activeCount":95},[],{"trials":2967,"activeCount":95},[],{"trials":2969,"activeCount":95},[2970],{"nctId":1991,"briefTitle":1992,"status":548,"phases":2971,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":1996,"conditions":2972,"interventions":2973},[83,84],[33,1998],[1968,2000,2001,1988,1989,2002,2003],{"trials":2975,"activeCount":95},[],{"trials":2977,"activeCount":95},[],{"trials":2979,"activeCount":95},[],{"intervention":2002,"totalTrials":12,"cells":2981},{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2992,"PHASE4":2994,"NA":2996},{"trials":2983,"activeCount":95},[],{"trials":2985,"activeCount":95},[],{"trials":2987,"activeCount":95},[2988],{"nctId":1991,"briefTitle":1992,"status":548,"phases":2989,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":1996,"conditions":2990,"interventions":2991},[83,84],[33,1998],[1968,2000,2001,1988,1989,2002,2003],{"trials":2993,"activeCount":95},[],{"trials":2995,"activeCount":95},[],{"trials":2997,"activeCount":95},[],{"intervention":2003,"totalTrials":12,"cells":2999},{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3010,"PHASE4":3012,"NA":3014},{"trials":3001,"activeCount":95},[],{"trials":3003,"activeCount":95},[],{"trials":3005,"activeCount":95},[3006],{"nctId":1991,"briefTitle":1992,"status":548,"phases":3007,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":1996,"conditions":3008,"interventions":3009},[83,84],[33,1998],[1968,2000,2001,1988,1989,2002,2003],{"trials":3011,"activeCount":95},[],{"trials":3013,"activeCount":95},[],{"trials":3015,"activeCount":95},[],{"intervention":3017,"totalTrials":12,"cells":3018},"BNT152",{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3033,"PHASE3":3035,"PHASE4":3037,"NA":3039},{"trials":3020,"activeCount":95},[],{"trials":3022,"activeCount":95},[3023],{"nctId":3024,"briefTitle":3025,"status":548,"phases":3026,"primaryCompletion":3027,"completion":3027,"start":3028,"enrollment":3029,"conditions":3030,"interventions":3031},"NCT04710043","Dose Escalation Trial of BNT152+153 in Patients With Cancer",[83],"2025-09-10","2021-06-08",86,[20],[3017,3032],"BNT153",{"trials":3034,"activeCount":95},[],{"trials":3036,"activeCount":95},[],{"trials":3038,"activeCount":95},[],{"trials":3040,"activeCount":95},[],{"intervention":3032,"totalTrials":12,"cells":3042},{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3051,"PHASE3":3053,"PHASE4":3055,"NA":3057},{"trials":3044,"activeCount":95},[],{"trials":3046,"activeCount":95},[3047],{"nctId":3024,"briefTitle":3025,"status":548,"phases":3048,"primaryCompletion":3027,"completion":3027,"start":3028,"enrollment":3029,"conditions":3049,"interventions":3050},[83],[20],[3017,3032],{"trials":3052,"activeCount":95},[],{"trials":3054,"activeCount":95},[],{"trials":3056,"activeCount":95},[],{"trials":3058,"activeCount":95},[],{"intervention":750,"totalTrials":12,"cells":3060},{"EARLY_PHASE1":3061,"PHASE1":3063,"PHASE2":3069,"PHASE3":3071,"PHASE4":3073,"NA":3075},{"trials":3062,"activeCount":95},[],{"trials":3064,"activeCount":95},[3065],{"nctId":740,"briefTitle":741,"status":742,"phases":3066,"primaryCompletion":744,"completion":744,"start":745,"enrollment":95,"conditions":3067,"interventions":3068},[83],[15],[44,748,749,750],{"trials":3070,"activeCount":95},[],{"trials":3072,"activeCount":95},[],{"trials":3074,"activeCount":95},[],{"trials":3076,"activeCount":95},[],{"intervention":3078,"totalTrials":12,"cells":3079},"Lipo-MERIT",{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3094,"PHASE3":3096,"PHASE4":3098,"NA":3100},{"trials":3081,"activeCount":95},[],{"trials":3083,"activeCount":95},[3084],{"nctId":3085,"briefTitle":3086,"status":548,"phases":3087,"primaryCompletion":3088,"completion":3088,"start":3089,"enrollment":3090,"conditions":3091,"interventions":3093},"NCT02410733","Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma",[83],"2023-06-20","2015-03",119,[3092],"Melanoma",[3078],{"trials":3095,"activeCount":95},[],{"trials":3097,"activeCount":95},[],{"trials":3099,"activeCount":95},[],{"trials":3101,"activeCount":95},[],{"intervention":3103,"totalTrials":12,"cells":3104},"BNT162b2 Bivalent (original\u002FOmicron BA.4\u002FBA.5) 30 mcg",{"EARLY_PHASE1":3105,"PHASE1":3107,"PHASE2":3123,"PHASE3":3125,"PHASE4":3127,"NA":3129},{"trials":3106,"activeCount":95},[],{"trials":3108,"activeCount":95},[3109],{"nctId":3110,"briefTitle":3111,"status":548,"phases":3112,"primaryCompletion":3113,"completion":3113,"start":3114,"enrollment":3115,"conditions":3116,"interventions":3117},"NCT05541861","Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People",[83],"2024-11-22","2022-11-08",383,[17,15],[3103,3118,3119,3120,3121,3122],"BNT162b4 5 mcg","BNT162b4 10 mcg","BNT162b4 15 mcg","BNT162b4 30 mcg","BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg",{"trials":3124,"activeCount":95},[],{"trials":3126,"activeCount":95},[],{"trials":3128,"activeCount":95},[],{"trials":3130,"activeCount":95},[],{"intervention":3118,"totalTrials":12,"cells":3132},{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3141,"PHASE3":3143,"PHASE4":3145,"NA":3147},{"trials":3134,"activeCount":95},[],{"trials":3136,"activeCount":95},[3137],{"nctId":3110,"briefTitle":3111,"status":548,"phases":3138,"primaryCompletion":3113,"completion":3113,"start":3114,"enrollment":3115,"conditions":3139,"interventions":3140},[83],[17,15],[3103,3118,3119,3120,3121,3122],{"trials":3142,"activeCount":95},[],{"trials":3144,"activeCount":95},[],{"trials":3146,"activeCount":95},[],{"trials":3148,"activeCount":95},[],{"intervention":3119,"totalTrials":12,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3159,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3152,"activeCount":95},[],{"trials":3154,"activeCount":95},[3155],{"nctId":3110,"briefTitle":3111,"status":548,"phases":3156,"primaryCompletion":3113,"completion":3113,"start":3114,"enrollment":3115,"conditions":3157,"interventions":3158},[83],[17,15],[3103,3118,3119,3120,3121,3122],{"trials":3160,"activeCount":95},[],{"trials":3162,"activeCount":95},[],{"trials":3164,"activeCount":95},[],{"trials":3166,"activeCount":95},[],{"intervention":3120,"totalTrials":12,"cells":3168},{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3177,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3170,"activeCount":95},[],{"trials":3172,"activeCount":95},[3173],{"nctId":3110,"briefTitle":3111,"status":548,"phases":3174,"primaryCompletion":3113,"completion":3113,"start":3114,"enrollment":3115,"conditions":3175,"interventions":3176},[83],[17,15],[3103,3118,3119,3120,3121,3122],{"trials":3178,"activeCount":95},[],{"trials":3180,"activeCount":95},[],{"trials":3182,"activeCount":95},[],{"trials":3184,"activeCount":95},[],{"intervention":3121,"totalTrials":12,"cells":3186},{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3195,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3188,"activeCount":95},[],{"trials":3190,"activeCount":95},[3191],{"nctId":3110,"briefTitle":3111,"status":548,"phases":3192,"primaryCompletion":3113,"completion":3113,"start":3114,"enrollment":3115,"conditions":3193,"interventions":3194},[83],[17,15],[3103,3118,3119,3120,3121,3122],{"trials":3196,"activeCount":95},[],{"trials":3198,"activeCount":95},[],{"trials":3200,"activeCount":95},[],{"trials":3202,"activeCount":95},[],{"intervention":3122,"totalTrials":12,"cells":3204},{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3213,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3206,"activeCount":95},[],{"trials":3208,"activeCount":95},[3209],{"nctId":3110,"briefTitle":3111,"status":548,"phases":3210,"primaryCompletion":3113,"completion":3113,"start":3114,"enrollment":3115,"conditions":3211,"interventions":3212},[83],[17,15],[3103,3118,3119,3120,3121,3122],{"trials":3214,"activeCount":95},[],{"trials":3216,"activeCount":95},[],{"trials":3218,"activeCount":95},[],{"trials":3220,"activeCount":95},[],{"intervention":3222,"totalTrials":12,"cells":3223},"BNT165b1",{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3237,"PHASE3":3239,"PHASE4":3241,"NA":3243},{"trials":3225,"activeCount":95},[],{"trials":3227,"activeCount":95},[3228],{"nctId":3229,"briefTitle":3230,"status":548,"phases":3231,"primaryCompletion":3232,"completion":3233,"start":3234,"enrollment":107,"conditions":3235,"interventions":3236},"NCT05581641","Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria",[83],"2024-02-23","2024-09-06","2022-12-15",[2936],[3222],{"trials":3238,"activeCount":95},[],{"trials":3240,"activeCount":95},[],{"trials":3242,"activeCount":95},[],{"trials":3244,"activeCount":95},[],{"intervention":3246,"totalTrials":12,"cells":3247},"BNT331",{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3262,"PHASE3":3264,"PHASE4":3266,"NA":3268},{"trials":3249,"activeCount":95},[],{"trials":3251,"activeCount":95},[3252],{"nctId":3253,"briefTitle":3254,"status":548,"phases":3255,"primaryCompletion":3256,"completion":3256,"start":3257,"enrollment":3258,"conditions":3259,"interventions":3261},"NCT06469164","A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis",[83],"2025-07-31","2024-07-01",102,[3260],"Bacterial Vaginosis",[3246],{"trials":3263,"activeCount":95},[],{"trials":3265,"activeCount":95},[],{"trials":3267,"activeCount":95},[],{"trials":3269,"activeCount":95},[],{"intervention":3271,"totalTrials":12,"cells":3272},"IVAC_W_bre1_uID",{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3289,"PHASE3":3291,"PHASE4":3293,"NA":3295},{"trials":3274,"activeCount":95},[],{"trials":3276,"activeCount":95},[3277],{"nctId":3278,"briefTitle":3279,"status":548,"phases":3280,"primaryCompletion":3281,"completion":3282,"start":3283,"enrollment":3284,"conditions":3285,"interventions":3287},"NCT02316457","RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID",[83],"2020-05-13","2023-05-17","2016-10",42,[3286],"Breast Cancer (Triple Negative Breast Cancer (TNBC))",[3271,3288],"IVAC_W_bre1_uID\u002FIVAC_M_uID",{"trials":3290,"activeCount":95},[],{"trials":3292,"activeCount":95},[],{"trials":3294,"activeCount":95},[],{"trials":3296,"activeCount":95},[],{"intervention":3288,"totalTrials":12,"cells":3298},{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3307,"PHASE3":3309,"PHASE4":3311,"NA":3313},{"trials":3300,"activeCount":95},[],{"trials":3302,"activeCount":95},[3303],{"nctId":3278,"briefTitle":3279,"status":548,"phases":3304,"primaryCompletion":3281,"completion":3282,"start":3283,"enrollment":3284,"conditions":3305,"interventions":3306},[83],[3286],[3271,3288],{"trials":3308,"activeCount":95},[],{"trials":3310,"activeCount":95},[],{"trials":3312,"activeCount":95},[],{"trials":3314,"activeCount":95},[]]